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Abstract 
Delayed drug hypersensitivity reactions (DHRs) are idiosyncratic, T-cell mediated, and can 
present days after exposure to the culprit drug, resulting in varying degrees of skin rashes. 
We hypothesize that differences in activated peripheral T cell subsets and types of mediators 
released produce different clinical phenotypes of drug hypersensitivity reactions to 
sulphnamides and beta-lactam antibiotics.  
We recruited participants with previous DHRs to sulfamethoxazole or beta-lactams . 
Peripheral blood mononuclear cells were isolated from participants. T-cell subset 
proliferation and activation was assessed by T-cell specific surface markers using 3H-
thymidine incorporation and flow cytometry, and secreted cytokines were measured using 
bead-based detection. 
There is insufficient evidence to conclude which T-cell subtypes are involved in different 
DHR clinical presentations. There were no significant differences between DHR participants 
and controls. More participants should be recruited to increase study power and range of 
clinical presentations, and consider alternate methods of identifying T-cells and modulators 
of interest. 
Keywords 
Drug Hypersensitivity, T cell, sulfamethoxazole, beta-lactam antibiotics 
 
iii 
 
Summary for Lay Audience 
Delayed drug hypersensitivity reactions (DHRs) are reactions that are somehow caused by 
the immune system interacting with the drug. DHRs typically occur days after taking the 
drug, usually result in a skin rash, and are mediated by T cells. It is still unclear how the T 
cells cause DHRs, however there are several theories. Two commonly prescribed drugs that 
cause these reactions are sulfamethoxazole and beta-lactam antibiotics. We believe that 
reactions mediated by different types of T cells in the blood lead to the various types of skin 
rashes caused by DHRs.  
We recruited participants who had previously visited Dr. Rieder’s drug allergy clinic and had 
previously tested positive for a DHR to either sulfamethoxazole or beta-lactams. We took a 
sample of blood from each participant, isolated a group of blood cells from the samples 
called “peripheral blood mononuclear cells” (PBMCs), which contains T cells. We tested 
these cells in different ways to see how the cells were responding to the drug. We used a 
technique called scintillation counting to determine if the PBMCs were growing when 
incubated with the drug, flow cytometry to see which type of T cell was activated in response 
to the drug, and Luminex to determine which molecules (cytokines) the PBMCs produced 
after incubation. 
We have insufficient evidence to conclude which type of T cell is involved in each skin 
reaction. Overall, we found no differences between T cell subset activation in response to 
exposure to the drug treatment, while other studies have previously found differences. 
Changes in the methods, including increasing number of T cells used in the analysis and 
expanding the number of T cell subsets analyzed by flow cytometry, and increasing the 
cytokines analyzed by Luminex, could improve results. We only recruited eight participants, 
to increase the strength of the conclusions we will need to increase the number of 
participants. We conclude that some changes in methods could improve and produce more 
reliable results. 
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Chapter 1  
1 Introduction 
Drugs and medications are an important part of care for many patients, including some of 
our population’s most vulnerable and sick. However, while many individuals can take a 
drug and benefit from its therapeutic effects, some can experience harmful and 
potentially fatal reactions. Adverse drug reactions cause a number of problems, which in 
addition to the effects on the health of the patient can include unexpected effects due to 
suspected risk of adverse drug reactions including mis-labeling, use of less effective 
medications and overuse of other types of drugs such as antibiotics leading to resistance. 
1.1 Background Information 
1.1.1 Definitions 
There have been many definitions suggested for adverse drug reactions (ADR) since the 
World Health Organization (WHO) published their definition in 1972. Specifically, a 
drug reaction is classified as adverse when, taken at a standard dose, it causes a noxious 
and unintended reaction.1 The WHO also defines a drug as a substance or product whose 
use can benefit the recipient either physiologically or psychologically.1 
An adverse drug event is an undesired outcome that occurs while a patient is taking a 
drug, but the adverse outcome is not necessarily attributable to the drug, for example an 
overdose. This is different from an adverse drug effect, which is an adverse outcome that 
can be attributed to some action of the drug the patient took, an example being a side 
effect.2 
The term “drug allergy”, however, is often used out of context to describe conditions that 
are not mechanistic allergies.3 This unhelpful labeling has prompted Johansson et al. to 
suggest revised nomenclature for mechanistic discussions on ADRs.4 They recommend 
the term ‘hypersensitivity’ be used to describe reproducible signs or symptoms due to 
exposure to a stimulus at a dose that is normally tolerated. They also recommend the term 
‘allergy’ be used only to describe a hypersensitivity reaction that has a specific and 
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defined immunologic mechanism. When there are other mechanisms that are not 
immune-mediated, then non-allergic hypersensitivity can be used.  
1.1.2 Prevalence 
Adverse drug reactions are a burden on the individual and expensive to the health care 
system. In 1994 it was estimated that in the United States 106 000 patients died of 
2,216,000 hospitalized with ADRs as a result of a drug injury.5 ADRs are responsible for 
approximately 5% of all hospital admissions and affected 10-20% of all hospital 
inpatients. In addition to the burden placed on physicians and the healthcare system, 
ADRs increase the cost of an individual’s care and negatively affect their quality of life.6–
10 
1.1.3 Economic Impact 
Of all ADRs, approximately 20% are drug hypersensitivity reactions (DHRs).11,12 Many 
people in the USA (20-35%) report having at least one prior reaction to medication.11,13,14 
However, not all of these reported reactions are true ADRs: only 1-5% of people with a 
reported drug allergy actually have one.11,15 This overreporting can compromise patient 
care, including the prescribing of less effective treatment options and potentially 
increasing the cost of care. For example, using alternative antibiotics has been associated 
with increased treatment failures and higher rates of nosocomial infections (eg. 
Methicillin resistant Staphylococcus aureus, MRSA).11,16,17 People who report penicillin 
allergy also spend longer times in hospital than non-allergic patients,11,18 and have higher 
costs associated with their prescription medications.11,19–22 Treating ADRs is expensive, 
potentially costing thousands of dollars to treat.11,23 Based on a report from Canada, 
performing graded oral challenges in children before prescribing antibiotics based on 
reported allergy is able to save money.11,24 
1.1.4 Difficulties and Considerations in Diagnosing ADRs 
Accurate, reliable, and safe tests are important for both predicting and confirming ADRs. 
Currently, the risks for many ADRs are overestimated, particularly with reactions to 
penicillin. In a recent survey,25 approximately 65% of surveyed patients responded they 
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would not continue to use a drug even if told by their physician that the reaction was not 
caused by the drug in question. A penicillin allergy is the most common drug allergy 
charted during hospital admissions and has been linked to increased time in hospital; 
increased reliance on broad-spectrum antibiotics; and increased prevalence of 
Clostridium difficile, MRSA, and vancomycin-resistant Enterococcus infections.26 There 
are consequences of overdiagnosis of drug allergy, including an increase in drug-resistant 
infections.3,18,27 However, there is no consensus on the extent of over-diagnosis. Drug 
allergies are often self-reported, and the frequency can be as high as 39%.3,28 Sousa-Pinto 
et al., after completing a meta-analysis, found that 8.3% of their participants had self-
reported a drug allergy.3 
In addition to overcoming personal conviction, accurate diagnoses are also important, as 
inaccurate diagnoses prevent patients from being treated with potentially beneficial 
drugs. However, the opposite of this is also true. If a patient is told they are not sensitive 
to a drug and is then treated with the drug, they could be subjected to a potentially fatal 
and avoidable reaction.29,30 Adverse drug reactions can also present similarly to other 
diseases, so it can be difficult to discriminate between the illnesses.30 Some drug-induced 
rashes can be indistinguishable from rashes produced by other agents, such as viruses.31  
ADRs and DHRs typically affect more children and women than men, for reasons that 
can either be physiological or sociological. Women are prescribed more antibiotics than 
men. In a meta-analysis across nine high-income countries, women in general across all 
ages are 27% more likely to receive an antibiotic, and up to 40% more likely in the 16-54 
age group.32 In the USA specifically, women are prescribed more antibiotics for 
respiratory tract infections (RTIs) than men are.32,33 In England in 2019, an analysis by 
Smith et al. found that adult women receive almost twice as many antibiotic prescriptions 
than men, while elderly women specifically receive 67.4% more.34 They also note some 
drugs are simply more commonly prescribed to women than men, however there is still a 
disparity of 70% more prescriptions when urinary tract infections (UTIs) are removed 
from the analysis. In addition to being prescribed more antibiotics alone, women are 
more likely to consult with their general practitioner (GP) more than men. In the USA, 
men visit their GP less, but also exhibit more risk-taking and health-compromising 
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behaviours and conditions than women do, including obesity, smoking, and drinking.32 
Smith et al. describe women seeking primary care 80% more than men across the 12 
conditions they examined.34  
In addition to utilization differences in prescribing, there are potentially pharmacological 
differences in women compared to men that would lead to an increased incidence of 
ADRs. For example, Rademaker demonstrated that cytochrome P450 (CYP45) 3A4 is 
higher in women by up to 40%, which they attribute to different steroid hormones 
affecting CYP3A4 activity due to competitive inhibition.35,36 The author suggests that 
metabolites generated due to drug metabolization by CYP3A4 might be the cause of the 
ADRs. Rademaker also noted the differences in conjugation of drugs between men and 
women – specifically referencing temazepam, which is conjugated and cleared faster in 
men than women.35,37 Kando observed that women have higher concentrations of drug in 
plasma than men and receive more drug due to a smaller body mass.38 In addition, Kando 
reviewed how hormones can also have an influence on ADRs affecting more women.38 
Different levels of estrogen, progesterone, and testosterone may affect enzyme activity 
throughout the menstrual cycle, which can affect the metabolization of drugs.38 
1.2 Classification of ADRs 
The most common classification system for ADRs divides ADRs into two main types: 
Type A and Type B. Type A reactions, the most common, are predictable since the 
reaction is related to the known pharmacological action of the drug. These reactions are 
dose-dependent and essentially exhibit amplified effects of the drug. By reducing the 
dose or eliminating the drug from the patient’s therapy, the reaction can often be 
reversed. Type B reactions, however, are generally more unpredictable due to the 
potential for delayed onset of signs and symptoms. These often do not exhibit a dose-
dependent relationship and the effects are not usually related to the known drug 
pharmacology.39 Type B, or “idiosyncratic adverse drug reactions,” are further 
subdivided into two groups: immune-mediated, or hypersensitivity reactions, and non-
immune mediated reactions. A breakdown of this classification is outlined in Figure 1-1.  
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1.2.1 Non-Immune Mediated Reactions 
Pseudoallergy is another term for a reaction that is clinically a hypersensitivity but is not 
immune-mediated. It is classified here because these reactions imitate other reactions and 
can range from being mild to causing anaphylaxis.40 While pseudoallergy can be similar 
to anaphylaxis, unlike anaphylaxis, pseudoallergy results from mast cells and basophils 
releasing mediators. This process is not mediated by immunoglobulin E (IgE).41,42 This 
leads to histamine release, complement activation, among others.41,43 One example of this 
is vancomycin-induced redman syndrome. Mast cells and basophils degranulate, 
releasing histamine, in a manner which is not IgE-dependent,44 resulting in a flushed face, 
neck, and ears, and is often accompanied by itching.45 
1.2.2 Immune-Mediated Reactions 
These reactions have been further divided into subtypes. These were originally outlined 
by Gell and Coombs46 and have been modified slightly by the addition of further 
subclassifications.  
Type I 
Type I reactions are mediated by IgE, bound to mast cells with Fc-IgE receptors. The 
mast cells release histamine and cause an immediate reaction, including urticaria and 
fatal anaphylaxis. The reaction can start within seconds of a parentally applied drug, or 
within minutes of oral intake. Most of these reactions result in pruritis or urticaria, 
however they can escalate to life-threatening reactions such as anaphylaxis.40 
Type II 
Type II reactions involve the formation of complement-fixing IgG antibodies and 
occasionally IgM that interact with Fc-IgG receptors on macrophages, natural killer (NK) 
cells, granulocytes, etc. In these reactions, immune complex activation occurs on the cell 
surface of erythrocytes, leukocytes, platelets, hematopoietic precursor cells, etc.40 There 
are several ways in which this can occur, including opsonization of cells by activated 
complement components leading to phagocytosis, antibody deposition leading to 
macrophage and neutrophil recruitment, and anti-body-dependent cell-mediated 
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cytotoxicity due to eosinophil degranulation.47 Pichler proposes that, specifically to 
drugs, the drug can be adsorbed to the membrane, creating a new antigenic complex with 
the cell membrane.40 Hemolytic anemia and thrombocytopenia have been listed as side 
effects to various drugs, including penicillin, cephalosporins, quinidine for the former, 
and quinine, quinidine, and sulphonamides for the latter.40 
Type III 
In Type III reactions, immune complexes are formed, which is a common event in a 
normal immune response and does not typically result in symptoms. Efficiency of 
treatment can decrease if immune complexes are formed by drug-protein interactions. It 
is not fully understood why an immune complex disease forms, and several reasons can 
be speculated as to why these occur. An inability to remove complexes can result in 
inappropriate deposition, leading to recruitment of other immune cells, leading to 
hypersensitivity, small vessel vasculitis and/or serum sickness.40  
Type IV 
Type IV are T cell mediated hypersensitivity reactions. Originally, Gell and Coombs did 
not subclassify these reactions, however with new knowledge of the functions of T cells 
and the types of inflammation they cause, these reactions have been further subclassified 
from Type IVa to Type IVd.40  
Type IVa: These are Th1-type immune reactions, involving the activation of macrophages 
by IFN-γ and complement-fixing antibody production. This can possibly lead to co-
activation of CD8+ T cells, leading to a combination of Type IVa and IVc reactions.40 
Type IVb: These are Th2-type immune reactions, with cytokines IL-4, -13, and -5 which 
promote mast cell and eosinophil responses.40  
Type IVc: T cells can migrate to the tissue and kill different cells with cytotoxic 
molecules such as perforin and granzyme B. Cytotoxic T cells (CD8+ T cells) are 
involved in maculopapular or bullous skin diseases, acute generalized exanthematous 
pustulosis (AGEP), and contact dermatitis.40  
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Type IVd: This reaction involves T cells coordinating neutrophilic inflammations in the 
skin, such as in AGEP.40 
 
Figure 1-1: Schematic of ADR classification 
1.3 Pathophysiology of DHRs 
There are several competing hypotheses that attempt to explain the mechanism that drives 
T cell-mediated drug hypersensitivity reactions. Not all drug reactions support a singular 
hypothesis, which led to the development of several hypotheses. These hypotheses are 
modeled in Figure 1-2.  
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Figure 1-1: Schematic of proposed hypotheses of DHR mechanisms 
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1.3.1 The Hapten Hypothesis 
The hapten/pro-hapten mechanism describes how small, low-molecular weight 
compounds (<1000 D) are able to elicit an immune response.40,48–51 The concept of a 
“hapten” driving an immune response was first published around 1935 by Landsteiner 
and Jacobs. They theorized that small molecules themselves were not immunogenic, but 
became immunogenic once bound to a protein.52 Subsequently the hapten hypothesis was 
further elucidated. The hypothesis is essentially that a hapten binds to a carrier molecule 
such as a protein and the modified hapten-carrier molecule can then generate an immune 
response. Similarly, pro-haptens, which are not chemically reactive, are first metabolized 
in the liver where they can then bind to a peptide.40,48,53–55 Beta-lactam antibiotic allergy 
was felt to be an example of a drug reaction that followed the hapten mechanism. This 
process occurs due to nucleophilic attack on the drug molecule, opening the beta-lactam 
ring, resulting in a penicilloyl-protein adduct, which can cause an immune response.56,57 
These drugs often bind to albumin as its carrier protein,58 since it is the most abundant 
protein in serum.57  
1.3.2 The P-I Hypothesis 
A competing hypothesis is the p-i (direct pharmacological interaction of drugs with 
immune receptors) hypothesis, that speculates that chemically inert drugs can activate T 
cells via specific T cell receptors (TCRs) that interact with the specific drugs.40,48,49,59 
This hypothesis postulates that the drug-TCR interaction is independent from metabolism 
and processing. The drug binds to the TCR directly, and the major histocompatibility 
complex (MHC) is not covalently modified. However, MHC binding is still required for 
full T cell activation.60 The p-i hypothesis was developed in response to the 
hapten/prohapten hypothesis stating that a low molecular weight drug must bind to a 
protein to initiate an immune response, and contradicts the necessity of protein binding. 
Specifically, Pichler considers how some chemically inert drugs, which cannot become 
haptenized in the skin, result in positive skin tests.59–62  
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1.3.3 The Danger Hypothesis 
The danger hypothesis was proposed as an alternative to the self/non-self concept of 
immune reactions. Injured cells send danger or alarm signals, which activate antigen-
presenting cells (APCs).63 In this hypothesis, the immune system is triggered by damage 
signals instead of recognizing non-self antigens.63–65 It is suggested that the drug or its 
reactive metabolite must also cause cell damage for a drug reaction to occur.66 One 
possibility is that during drug metabolization, accumulation of reactive metabolites can 
lead to cell death, which generates danger signals.67 It has been suggested that there are 
other factors that can act as a danger signal that would increase a patient’s chance of 
having a drug reaction. Administering a patient with mononucleosis ampicillin will often 
develop a skin rash.66,68 An example is the 50% chance of developing a drug reaction 
when sulfamethoxazole administered to patients with AIDS versus 0.5% in uninfected 
patients.66,69  
1.3.4 The Altered Repertoire Hypothesis 
The altered repertoire hypothesis describes how a drug can interact with human leukocyte 
antigen (HLA) class I molecules, leading to the presentation of altered peptides that can 
cause an immune reaction.70 There has recently been increasing support for this 
hypothesis. As an example, abacavir is able to activate CD8+ cells in an HLA-B*57:01-
restricted manner, leading to a hypersensitivity reaction.71 After deducing that other 
hypotheses could not support this observation, Ostrov et al. found that abacavir can bind 
to the peptide binding groove of HLA-B*57:01 allowing for the presentation of novel 
peptides that appear as foreign, triggering a response from CD8+ cells.72  
1.3.5 Reactive Metabolite Hypothesis 
The reactive metabolite hypothesis suggests that reactive metabolites of a drug are 
responsible for drug reactions, instead of the parent drug.73 This can either be through 
drug metabolism or if the drug damages a cell and produces danger signals.73 The 
reactive metabolite of many drugs is responsible for its activity, and this typically occurs 
during metabolization by enzymes in cells such as hepatocytes.74,75 Drug metabolites can 
accumulate, resulting in an endogenous molecule that can then be taken up by antigen 
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presenting cells and presented to T cells.74 One proposed example is the metabolic 
pathway of sulfamethoxazole, which leads to reactive metabolites.73 This hypothesis has 
been linked to the hapten hypothesis, in that reactive metabolite generation may be the 
initial event triggering an immune response by the creation of a reactive metabolite that, 
when complexed with a cellular macromolecule, acts as a hapten to generate an immune 
response.76 
1.4 Immune-Mediation of DHRs 
The innate immune system (“pro-inflammatory” immune response) is responsible for 
rapid recognition of an antigen. This system consists of neutrophils, macrophages, 
monocytes, NK cells, dendritic cells (DCs), among others, which direct and inform the 
adaptive immune system.77  
The adaptive immune system is responsible for both specific and memory responses, and 
is composed of B cells, αβ T cells, and γδ T cells. Upon recognizing or being presented 
with an antigen, these cells expand to perform specific functions: B cells become plasma 
cells, which make large quantities of immunoglobulins, and T cells (specifically αβ) 
either directly kill cells or recruit other cell types. While most of these cells die after the 
culmination of the immune response, some – such as memory T cells – continue to live 
for many years in order to protect against reinfection after initial contact.77 
1.4.1 Composition of PBMCs 
Peripheral blood mononuclear cells (PBMC) are a cellular population that can be isolated 
from peripheral blood, and essentially consist of any blood cell featuring a single round 
nucleus, which include lymphocytes, monocytes, NK cells, and dendritic cells (DCs).78 
These cells are separated from red blood cells, granulocytes (neutrophils, basophils, and 
eosinophils) by density gradient separation, whereas PBMCs are located in the low-
density layer (ie. less dense than 1.077 g/ml). Although there is some variability across 
individuals, PBMCs are typically composed of approximately 70-90% lymphocytes, 10-
20% monocytes, and 1-2% DCs. Of the lymphocytes, approximately 70-80% are CD3+ T 
cells, 5-10% B cells, and 5-20% NK cells. Typically within CD3+ lymphocytes, CD4+ 
and CD8+ cells are represented in a 2:1 ratio, respectively.78–82  
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1.4.2 Antigen-Presenting Cells 
Antigen-presenting cells (APCs) are cells at the overlap between the innate and acquired 
immune systems. DCs, B cells, and macrophages are all considered to be professional 
APCs. What distinguishes these APCs from other cells is the presence of abundant MHC 
class II receptors. Specifically, DCs and macrophages can detect and phagocytose 
substances (e.g. pathogen-associated molecular patterns (PAMPs), damage-associated 
molecular patterns (DAMPs)), parts of apoptotic cells, process antigen, and move to 
specific tissues (e.g. T cell zone of lymph node). B cells acquire antigen through the B 
cell receptor (BCR).83  
Some other cells, such as mast cells, basophils, eosinophils, neutrophils, innate lymphoid 
cells (ILCs), and CD4+ T cells have also been found to be able to induce MHC class II 
expression. However, this can only occur in certain immune environments and has not 
been researched extensively to conclude their role.83  
1.4.3 Dendritic Cells 
DCs are antigen-presenting cells (APCs) that modulate the immune response by 
stimulating B cells and T cells.84,85 These cells are located in most tissues throughout the 
body. They are stellate and have a multiplicity of MHC molecules on their surface.84,86 
There are two stages in the life of a DC: the immature and the mature stage. As an 
immature DC, these cells have few MHC molecules, capture antigens (with Fcγ and Fcε), 
but they cannot generate the appropriate stimulatory molecules for T cells (CD40, CD54, 
CD86). Immature DCs are able to phagocytose particles,84,87–90 sample antigens in 
phagocytic vesicles,84,91 and then express the appropriate receptors to stimulate T cells. 
Mature DCs, however, are terminally differentiated, and display many MHC class II 
molecules bound to antigen.84,92 They upregulate costimulatory molecules, then move to 
secondary lymphoid tissues to interact with T cells.  
1.4.4 B Cells 
B cells are “bursal” or “bone marrow” derived cells that date back to the origin of 
adaptive immunity in jawed vertebrates more than 500 million years ago.93,94 B cells 
13 
 
originate in the primary lymphoid tissue, which in humans is the bone marrow. In 
general, they undergo functional maturation in the spleen or lymph nodes, which are the 
secondary lymphoid organs, and then finally produce antibodies as plasma cells. These 
cells undergo functional rearrangement of Ig loci in the bone marrow: V, D, and J 
sequences at the H chain locus and V and J at the L chain loci.93,95 These allow for a 
diverse repertoire of B cell receptors in the B cell population. 
1.4.5 T Cells 
T cells have been previously shown to be involved with DHRs and it is believed that they 
are the central driver for common and important DHRs.53,54,96–104 However, the role(s) 
that different T cell subtypes and their mediators may have in the pathogenesis of Type 
IV DHRs, if any, have not been fully explored, nor has the impact of different T cells 
responses to clinical phenotypes of DHRs.   
1.4.5.1 Helper T Cells 
T helper cells (Th) are involved in the coordination of the adaptive immune response, 
primarily by the secretion of specific cytokines to recruit other cells toward infected 
areas. These cells are characterized by CD4+.105 Specific cytokine environments and 
master regulators are responsible for the many subtypes of Th cells that have been 
discovered. 
Th1 Cells 
T helper 1 (Th1) cells produce the cytokine interferon-γ (IFN-γ). They function to 
eliminate intracellular pathogens and are involved in two types of hypersensitivity 
reactions: cell-mediated and delayed.106,107 Additionally, Th1 cells are involved in the 
process of producing opsonins, complement-fixing antibodies, and can lead to 
macrophage activation.108  
Both IFN-γ and interleukin-12 (IL-12) are the cytokines in a naïve T cell’s environment 
that promote differentiation to Th1 subtype. IFN-γ inhibits Th2 cell differentiation while 
IL-12 promotes Th1 growth and does not affect Th2 cells.109–112 T-bet is the transcription 
factor that controls the expression of IFN-γ and is imperative for Th1 cell differentiation 
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from naïve CD4+ T cells. T-bet both activates the IFN-γ gene as well as induces 
exogenous production of IFN-γ.113 Th1 cells are found to be involved in organ-specific 
immune disorders, acute allograft rejection, contact dermatitis, among other immune 
disorders.108  
IFN-γ 
Th1 cells are defined by their secretion of IFN- γ, although many cells have been found to 
secrete this cytokine, including B cells, natural killer T cells (NKT), and professional 
APCs114–118 in addition to Th1, CD8+ T cells, and NK cells.114,119,120 Multiple studies have 
found that IFN-y is secreted by PBMCs isolated from study participants with a history of 
delayed type drug hypersensitivity. IFN-γ is secreted when drug-specific PBMCs are 
incubated with sulfamethoxazole (SMX)121 and piperacillin.104 In addition, Beeler et al. 
found that PBMCs from AGEP and severe exanthema patients secreted both IFN-γ and 
interleukin-13 (IL-13).122  
Th2 Cells 
Another subset of helper T cells are T helper 2 (Th2) cells. These are associated with 
extracellular (helminth) responses and stimulating damaged tissue repair. These secrete 
IL-4, -5, -6, -9, -10, and -13.106–108  
The cytokine IL-4 promotes the differentiation of a naïve CD4+ T cell to a Th2 
cell.109,123,124 During Th2 development, the transcription factor GATA-3 is upregulated. 
Conversely, it is downregulated during Th1 development.125–127  
Th2 cells are mediators in a variety of different disorders such as Omenn’s syndrome, 
reduced protection against extracellular pathogens, and chronic Graft vs. Host Disease.108  
IL-4 
IL-4 is a potent regulator of immunity,128 regulating immune functions such as Ig isotype 
class switching, B cell MHC class II expression, and differentiating certain Th cell 
lineages.129 IL-4 is also secreted by mast cells, eosinophils, and basophils in addition to 
Th2 cells.128 It was first described by Howard and Paul as a comitogen of B cells.128,130 
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IL-4 binds to IL-4R alpha. It can either produce type I signaling when also bound to 
gamma chain or type II when bound to IL-13Rα1.128,131,132 This Type I signaling is 
important for the polarization of naïve CD4+ T cells to Th2 cells.128  
IL-13 
IL-13 is a cytokine secreted by Th2 cells.106–108 It is able to induce the expression of MHC 
class II in human B cells and phenotypic changes in human monocytes. It also acts on 
human B cells by inducing proliferation and immunoglobulin production.133–136 In 
general, IL-13 has anti-inflammatory properties and plays a regulatory role in the 
immune response.  
IL-13 is secreted by T cells when drug-specific PBMCs are stimulated with either 
ampicillin (AMP) or SMX.137 It is also secreted by PBMCs from piperacillin-
hypersensitive patients when incubated with the culprit drug.104 Beeler et al. noted that 
PBMCs of patients with severe exanthema and AGEP secreted IL-13 as well as IFN-γ.122  
Th9 Cells 
Th9 cells are generated by naïve CD4+ cells exposed to TGF-ß and IL-4, and are 
characterized by their production of IL-9.138 In contrast, exposing naïve CD4+ cells to IL-
4 only leads to the differentiation of Th2 cells,138 and CD4+ cells to TGF-ß only leads to 
induced regulatory T cells (Treg).138–141 While Th2 cells also produce IL-9, Th9 cells 
produce IL-9 in much greater quantities and have a different role in the immune response 
than Th2 cells.142 These cells also require transcription factors STAT6, PU.1, IRF4, and 
GATA3.138,143–146 Although Th9 cells require such a specific environment to differentiate, 
they do exist in vivo, and can be found in the peripheral blood of allergic patients147 
among CLA+ (cutaneous leukocyte antigen positive) cells in the blood and skin.148,149  
IL-9 
Many cells are able to produce IL-9, including Th9 cells, innate lymphoid cells, mast 
cells, and neutrophils.138,142,150–153 However, Th9 cells produce IL-9 in a greater quantity 
than Th2.144,146 When T cells are activated by either PMA (phorbol myristate acetate) or 
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anti-CD3, IL-9 expression can be induced,154 with the addition of IL-2 further 
upregulating production.155 IL-9 promotes the survival of other cells, such as Th cells, 
mast cells, among others.156–158 IL-9 is also able to expand Th17 and Treg cells.138,159–162 
IL-9/Th9 cells have specifically been implicated in allergy and asthma. While IL-9 levels 
are increased in asthmatic patients,163 it is unknown if it is involved in other instances of 
allergy, such as anaphylaxis and atopic dermatitis.  
Th17 Cells 
T helper 17 (Th17) cells are a subset of Th cells that predominantly secrete IL-17. Th17 
cells were the third Th subset discovered164–166 and target extracellular bacteria and fungi. 
Interestingly, IL-17 was discovered before Th17 cells.167–169 When human naïve T cells 
are exposed to IL-1B and IL-6, Th17 cells are differentiated.139,170,171 The transcription 
factor important in the differentiation of Th17 cells is orphan nuclear receptor RORγt.172 
IL-17 does not inhibit Th1 or Th2 cells,173 but IL-12, IFN-γ, and IL-4 inhibit Th17 
cells.165,166,174–177  
While Th17 cells are characterized by IL-17 production, they also produce IL-17F, IL-22, 
and some TNF-α (tumour necrosis factor α), but IL-17A is predominant.164 Th17 cells 
produce TNF-α, IL-21, and IL-22, while it is debated whether they produce IL-
6.106,171,178–180 
Both Th17 cells and IL-17 have been implicated in several human diseases, including 
psoriasis, rheumatoid arthritis, systemic lupus erythematosus, endometriosis, asthma, 
irritable bowel syndrome, multiple sclerosis, atopic dermatitis, contact hypersensitivity, 
among others. In atopic dermatitis specifically, acute atopic dermatitis is associated with 
IL-17, but not chronically.164,181  
IL-17 
Th17 cells are a major producer of IL-17.106 IL-17 includes IL-17A, B, D, E, and F.182 
The functions of IL-17A and F include targeting fibroblasts, endothelial and epithelial 
cells, keratinocytes, macrophages, and stimulating and attracting neutrophils to 
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inflammation.178,183 IL-17 is important in extracellular bacteria defense171 and in the 
mobilization of neutrophils.169,171  
Interestingly, a previous study has shown that when PBMCs isolated from piperacillin-
hypersensitive patients are incubated with piperacillin, no IL-17 is produced. However, it 
is produced when incubated with PHA (phytohemagglutinin).104  
Th22 Cells 
Th22 cells are a terminally differentiated subtype of helper T cells that secrete IL-22. The 
cytokine environment required for the differentiation of naïve CD4+ T cells to Th22 cells 
is TNF-ß (tumour necrosis factor ß) and IL-6.184,185 The master regulator of Th22 cells is 
aryl hydrocarbon receptor.185–187  
Th22 cells were discovered due to their secretion of IL-22, but no signature cytokines of 
other T cell subtypes, such as IFN-γ, IL-4, and IL-17.184,185,187,188 However they do 
secrete small amounts of IL-13 and TNF-ß.184,188 
IL-22 
IL-22 is predominantly secreted by Th22 cells, but is also secreted in small amounts by 
Th1, Th2, and Th17 cells184 and is a member of the IL-10 family of cytokines.186 IL-22 
specifically binds to the IL-22 receptor (IL-22R), a heterodimeric receptor composed of 
IL-10Rß and IL-22Rα chains, which is abundant on epithelial cells.184,189 Specifically, IL-
22R is expressed in skin, liver, pancreas, intestine, lung, and kidney.186,190–192 IL-22 is 
also involved in wound healing.184,188,193 
IL-22 is implicated in some skin rashes, which can be a symptom of a DHR. For 
example, IL-22 is upregulated in psoriasis lesions.186,194–196 IL-22 is also found in greater 
amounts in atopic186,197 and contact dermatitis lesions.186,198  
Regulatory T cells (Treg) 
The immune system has the dual role of simultaneously protecting the host from 
pathogens or tumours while also preventing harm from excessive and harmful responses. 
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If an immune response is misdirected, it can produce an autoimmune disease.79 
Regulatory cells that act to prevent this are characterized as CD4+CD25+FoxP3+.139 Treg 
cells are a dominant mechanism for preventing excessive response and are specialized for 
immune suppression. Autoimmune and inflammatory responses can be caused by 
disruptions in the development or function of Tregs. When an adaptive immune response is 
occurring, both effector cells and Tregs are activated and recruited to the site of 
inflammation to maintain a balanced immune response, in both the quality and magnitude 
of the adaptive immune reaction.79  
Previous work has demonstrated the importance of Tregs are in controlling the immune 
response. Manipulating the thymus, as for example a thymectomy in a newborn, results in 
autoimmune damage and compromised immunity.79 In addition, removing autoimmune-
suppressive T cells from an organism can lead to autoimmune disease, while adding them 
back inhibits autoimmunity.199  
Regulatory T cells have many notable functions, but have important roles in inhibiting 
autoimmunity and protecting against tissue injury.139,200 The cytokine TGF-ß is important 
in differentiating naïve CD4+ T cells into Treg cells.139,201 
1.4.5.2 Cytotoxic T Cells 
Broadly, the role of a cytotoxic T lymphocyte (CTL) is to survey all nucleated body cells 
and destroy any that are a threat.202 When peptides are formed within the cell due to 
protein degradation, CTLs can detect the peptides when presented by MHC class I 
molecules.203 
A CTL needs to be in close contact to the target cell in order to kill it. The first 
mechanism is binding of Fas on the target cell to Fas ligand (FasL) on the effector cell, 
which transfers a death signal.204–206 The second method is performed through granule 
exocytosis. In the presence of calcium (Ca2+), granules are exocytosed into the space 
between the target and effector cells, causing holes to be formed within the target cell 
membrane.207 Examples of these “granules” include perforin,208 and granzymes A and 
B.209  
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Perforin 
Perforin is a protein involved in granule exocytosis in CTLs. Upon polymerization, 
perforin forms pores in the membrane of a target cell.210,211 These pores then disrupt ion 
gradients in a cell and result in osmotic lysis of the target cell.212,213 Both CTLs and NK 
cells express perforin.210,214–216 Perforin has a major role in pathologies such as graft 
rejection and immune responses against viruses.205,210,217,218 When Kagi et al. generated 
perforin-deficient mice, the mice had normal numbers of CD8+ and NK cells, however 
several immune functions were compromised, including antiviral and transplantation 
antigen-specific CTL activity.219 These mice could not clear a lymphocytic 
choriomeningitis virus infection and also had a diminished ability to control the growth 
of tumours. However, even in the absence of perforin, there was some lytic activity 
which was less effective.  
Fas 
Apoptosis-mediated cell killing by CTLs is able to explain the ability of CD8+ cells in 
perforin-deficient mice to kill target cells. The cell surface receptor, FasR, can lead to 
apoptotic cell death.220–222 When FasR- or FasL- mice are generated, they suffer from 
similar pathologies of perforin- mice, including autoimmunity and accumulation of large 
numbers of lymphocytes. FasL- lymphocytes are able to kill cells, but at a reduced rate of 
approximately 10-30% compared to wild type CTLs.220 This residual lysis is probably 
due to perforin-mediated killing. An important finding was that perforin- CTLs were 
inactive against FasR-deficient target cells, meaning that these are the two pathways 
responsible for CTL-mediated cell death. Overall, Lowin concludes that perforin is likely 
responsible for approximately two thirds of CTL-mediated killing, while Fas is 
responsible for the remainder in vivo.220 One downfall of Fas-mediated killing is that 
FasR expression can be different on cells and can be modulated in certain circumstances, 
such as when some viruses are able to downregulate FasR expression on cells.220,221  
Granzyme 
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Perforin only causes membrane damage and is insufficient in explaining DNA 
fragmentation and apoptosis shown in CTL target cells.212,223 Therefore it was 
hypothesized that another molecule must be responsible for the DNA fragmentation and 
apoptosis, once it is released from the CTL and is able to enter the target cell via pores 
made by perforin.212,224 
1.4.5.3 The T Cell Receptor and Activation Markers 
T Cell Receptor 
T cell receptors are found on the surfaces of T cells responsible for recognizing antigen 
from other cells. They are made up of two polypeptides (α and β) linked by disulfide 
bonds. These polypeptides are associated with other invariant CD3 proteins.225–228 The α 
and β polypeptide chains are coded by the rearrangement of germline genes; these 
random associations allow for the production of thousands of different, mature genes.225 
The TCR recognizes antigens when they are bound to an MHC molecule.225  
CD69 
CD69 is an early membrane receptor, a membrane type II C-type lectin,121 and is 
expressed on activated, but not resting, lymphocytes.229 After activation, an early change 
that occurs in T cells is the induction of genes encoding cell surface molecules.230 CD69 
has been detected on cell surfaces within 1-2 hours after activation.230–232 There are other 
activation markers that exist, for example CD25, CD71, and HLA-DR,121,233–235 however 
CD69 is very commonly used for T cells because of how quickly it can be found on cell 
surfaces. T cells that are stimulated through the TCR (CD3) complex express 
CD69,230,232,236–238 therefore mitogens such as PHA and PMA are able to induce the 
expression of CD69 in lymphocytes.230,232,238,239 In addition to lymphocytes, CD69 is 
expressed on all bone-marrow derived cells except RBCs.229,240 In some instances, CD69 
can be expressed on B cells, neutrophils, and freshly isolated monocytes, however the 
mechanisms by which CD69 is induced are different from T cells.230 
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1.5 Drugs Commonly Associated with DHRs 
A number of drugs are associated with ADRs and DHRs, particularly antibiotics 
(especially beta-lactam antibiotics) and anti-convulsants,241,242 as well as NSAIDs (non-
steroidal anti-inflammatory drugs), anti-retrovirals (eg. Abacavir), sulfonamides, and 
allopurinol.242 One issue that is currently lacking in the literature is whether different 
drugs are linked to DHRs caused by different T cell subsets and whether different DHR 
phenotypes are associated with different T cell responses.  
1.5.1 Sulfamethoxazole 
Sulfamethoxazole (SMX) has been previously associated with DHRs. SMX has been 
previously shown to recognize or activate drug-specific T cell clones.55,243 Specifically, 
CD4+ and CD8+ T cells have previously been shown to be involved in reactions to 
SMX.103  
Sulfamethoxazole is typically prescribed with trimethoprim (TMP). Bacteria are obligate 
folic acid synthesizers, as opposed to humans who must obtain folic acid through diet. 
Both SMX and TMP take advantage of bacteria requiring folic acid to survive by 
inhibiting the synthesis of tetrahydrofolic acid, a necessary cofactor for bacterial DNA, 
thymidine, and purines.244 Typically, it is prescribed as 20 parts SMX to 1 part 
TMP.244,245 This is to provide synergistic antibacterial activity as SMX and TMP target 
the folic acid synthesis pathway at different steps, blockading two separate steps prevents 
bacterial resistance to either component alone.244,246  
The primary route of SMX clearance is via metabolism in the liver by N-acetyltransferase 
and N-glucoronyl-transferase; these enzymes lead to the production of non-toxic 
metabolites.243,247 CYP-450 also metabolizes a small amount of SMX into hydroxylamine 
(SMX-HA) which under physiology conditions is rapidly converted to 
nitrososulfonamide (SMX-NO).247,248 SMX-NO is extremely reactive and may be central 
to many hypersensitivity reactions.  
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1.5.2 Beta-lactam antibiotics 
Beta-lactam antibiotics have been previously implicated in T cell-mediated DHRs. It has 
been previously shown that CD4+ and CD8+ T cell clones could be activated by 
piperacillin in patients with cystic fibrosis and beta-lactam antibiotic hypersensitivity.100 
Brander et al. also found a heterogeneous T cell response (of CD4+ and CD8+ T cells) to 
penicillin-hypersensitive individuals.249  
Beta-lactam antibiotics are widely used for treating bacterial infections in humans, but 
can also cause many immune-mediated allergic reactions.250 β-lactam antibiotics inhibit 
cell wall synthesis in bacteria by inhibiting transpeptidases, inducing lysis and cell 
death.34,251 Bacteria have developed a resistance to beta-lactam antibiotics, making many 
drugs ineffective.27,252–254  
The basic structure of a penicillin consists of a beta lactam ring, which is condensed to a 
thiazolidine ring. At position 6 of the structural backbone, there is an amine-bonded side 
chain, which is different depending on the type of penicillin.250 Specifically, amoxicillin 
(AMX) is a type of penicillin. It is prescribed either alone or combined to clavulanic acid 
(CLV).255  
Beta-lactam antibiotics have a ring structure that is responsible for the reactive and 
antibiotic activity.256 Once opening, penicillin is rearranged to metabolic by-products, 
including penicillic acid, penilloic acid, and penicilloic acid. In addition, 6-
aminopenicillanic acid may be formed. Beta-lactamases may produce other metabolites, 
including penicilloic acid. While not anti-bacterial, these metabolites may form 
immunogenic conjugates with proteins.257  
Beta-lactams can cause both immediate reactions (typically occurring one hour after drug 
intake), and non-immediate reactions.258–260 In terms of the non-immediate DHRs, 
maculopapular or morbilliform exanthemas (MPE) are the most common.258,261 It has 
been previously shown that AMX may be mediated via the hapten hypothesis.57 
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1.6 Clinical Phenotype of DHRs 
DHRs can result in a variety of clinical phenotypes, which range in severity. It is not 
always known how some individuals experience a more severe rash than another when 
taking the same drug. Typically, with delayed type DHRs, exanthemas (widespread rash 
that expands quickly) are the most common.262 Several types of lesions also occur, 
including pustular, vesicular, and bullar, however maculopapular is the most common.262 
Examples of skin reactions that can occur include erythema multiforme, drug reactions 
with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson Syndrome and 
Toxic Epidermal Necrolysis (SJS/TEN), maculopapular exanthema, and fixed drug 
eruption.262,263 Some drugs have been previously associated with different eruptions, 
including AMX with bullous skin disease, MPE, and AGEP,49 and NSAIDs, phenytoin, 
SMX, and AMX have been observed to cause FDE. Some of these skin reactions have 
other accompanied symptoms, such as fever (can be seen with DRESS and SJS/TEN) 
headaches, malaise, and fatigue. In some cases, the reaction can induce an autoimmune 
response, with one example occurring with prolonged DRESS potentially leading to 
drug-induced lupus erythematosus. DHRs can also lead to systemic organ involvement. 
Eosinophilia is common, while drug-induced hepatitis,262,264 drug-induced nephritis, and 
serum sickness are more rare.262 
1.6.1 Skin Rashes 
There are many kinds of rashes, and many different diseases or sensitivities can result in 
very similar-looking rashes. Allergies can lead to a set of specific types of rashes. 
Schlossberg outlines several of these distinctive types of reactions well.265 A rash that is 
pruritic is characterized as severe itching.266 Maculopapular rash is a type of eruption 
characterized by macules (spots) and papules (bumps). There are several causes of 
maculopapular rash, including Lyme disease, Rickettsiosis, rubella, EBV (Epstein-barr 
virus), SLE (systemic lupus erythematosus), and allergy, among many more.265 Another 
type of rash are vesico-bullous rashes. Vesicles are small blisters, while bullae are large 
fluid-filled blisters. There are also several causes of these types of rashes, including 
herpes simplex virus, staphylococcemia, HIV (human immunodeficiency virus), and 
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allergy.265 Several cytokines that can be secreted by different T cell subsets have been 
described in association with certain skin rashes (described below).  
1.6.1.1 Stevens-Johnson Syndrome and Toxic Epidermal 
Necrolysis 
A very serious type of rash associated with ADRs are seen in Stevens-Johnson Syndrome 
and Toxic Epidermal Necrolysis (SJS/TEN), which are acute life-threatening illnesses 
that affect the mucous membranes and cause acute epidermal detachment.267–269 SJS and 
TEN are two conditions on a spectrum with varying degrees of skin necrosis defined by 
the percentage of body surface area (BSA) affected. SJS involves <10% BSA, SJS/TEN 
overlap is 10-30% BSA, and TEN is >30% BSA. SJS is fatal in approximately 10% of all 
patients, while TEN is fatal in 30-50%. The vast majority (80-95%) of TEN cases are due 
to ADRs. Other, less common, causes include recent immunization, acute graft-vs-host 
disease, and contrast medium. Early symptoms include fever, malaise, and sore throat 
followed by blistering, target lesions, and various degrees of skin detachment.267,270 The 
skin lesions typically start on the body’s trunk.267,270,271  
Murata et al. determined that increased soluble Fas ligand (sFasL) is associated with SJS-
TEN, by demonstrating that there was increased sFasL in five of seven cases before 
disease onset.272 This difference would set early SJS/TEN apart from other drug 
eruptions. The authors note that since sFasL can be due to cell apoptosis in other 
diseases, it is important that this test is used only on people experiencing a cutaneous 
adverse reaction with high risk for SJS/TEN. Nomura et al. obtained serum samples from 
people at the onset of SJS/TEN and compared the cytokine levels to those of people with 
other delayed-type ADRs.273 They found that patients with TEN had higher levels of 
TNF-α, IL-10 IL-1Rα, IL-6, and GM-CSF. Patients with drug-induced hypersensitivity 
syndrome (DIHS) had increased IL-5 when compared to erythema multiforme (EM) and 
maculopapular (MP) type rashes. DIHS and TEN had high IL-13 levels, while SJS and 
TEN had slightly elevated IFN-γ levels. Pro-inflammatory cytokines and anti-
inflammatory cytokines are especially increased in TEN. Once SJS/TEN symptoms 
improved, IFN-gamma, IL-10, IL-1Rα, and IL-6 levels decreased.273  
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CCL27 is production is augmented by TNF-α in keratinocytes by the NFκB pathway.274 
Wang et al wanted to know if CCL27 influences the course of SJS/TEN. In serum CCL27 
was elevated during SJS/TEN, but low in blister fluid.275 In contrast, they found serum 
TNF-α to be low, while blister TNF-α was high. They concluded that while both 
contribute to progression of SJS/TEN, their effects were different.275 Granulysin has also 
been found to be responsible for widespread keratinocyte death.98,270 Chung and Hung 
found granulysin RNA in the blister cells of SJS/TEN, and granulysin was found to be in 
greater concentrations than other cytotoxic molecules. Upon injecting the skin of mice 
with granulysin, the mice developed an SJS/TEN-like reaction.98,270  
1.6.1.2 Acute Generalized Exanthematous Pustulosis 
Acute generalized exanthematous pustulosis (AGEP) was previously classified as 
psoriasis as it looked similar and was very rare.276 However, Baker and Ryan observed 
that some people presenting with AGEP had no previous history of psoriasis, and their 
illness was acute, short, and did not recur. They therefore attributed it to an infection or 
drugs.277  
AGEP is characterized by a pustular rash with fever over 38 °C96,278 on edematous 
erythema with a high neutrophil count.96 AGEP will spontaneously resolve within 15 
days of onset.96,279  
Approximately 90% of all AGEP cases have been associated with drugs, specifically 
aminopenicillins.96,279 AGEP has been previously associated with IL-8 secretion by T 
cells.96  
1.6.1.3 Drug Reaction with Eosinophilia and Systemic Symptoms 
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS, also referred to as 
DIHS, Drug Induced Hypersensitivity Syndrome) is a drug reaction that has been found 
to result after treatment with sulfanimide, phenytoin, dapsone, allopurinol, etc.280–284 
DRESS has a late onset (typically 2-8 weeks after use), and also involves fever, 
eosinophilia, skin eruption, and lymphocyte activation.280,285 Chen et al. examined 
DRESS records from 60 former patients in a Taiwan medical centre.280 They found that 
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allopurinol was the most common cause, and the average latency period was 20.7 days. 
Some had other symptoms, including exfoliative dermatitis or blistering/purpuric 
eruption, in addition to the diffuse exanthematous eruption that all patients had. The 
authors also noted some differences in DRESS between patients, therefore questioned 
whether it is one disease or a spectrum. DRESS has been previously associated with IL-5 
and eotaxin secretion.286,287 
1.7 Diagnostic and Predictive Tests for DHRs 
1.7.1 In vivo 
In vivo tests that currently exist have been used to investigate DHRs are provocation tests 
and skin tests. Provocation tests work best for immediate reactions, since delayed 
reaction tests are not standardized enough for dose and symptom duration. There is also 
some difficulty with defining a positive result. Skin tests have been previously 
documented121,259,260,288–290 to have a low sensitivity and are only of utility in immediate 
hypersensitivity. They can be performed using a patch, a skin-prick, or an intracutaneous 
test.121  
1.7.2 In vitro 
1.7.2.1 Lymphocyte Toxicity Assay 
The lymphocyte toxicity assay (LTA) was developed from assays used to study metabolic 
differences between cells of patients and cells of controls. This assay uses isolated 
PBMCs to determine if there is greater cell death of drug hypersensitive patient cells 
compared to the cells of healthy control when incubated with the drug.291 Dr Rieder’s lab 
has had a long experience using these assays as a predictive and mechanistic tool for 
studying DHRs.29 
1.7.2.2 Lymphocyte Transformation Test 
The lymphocyte transformation test (LTT) is a widely used method in studying drug 
hypersensitivity.291 This test has been shown to be useful in exploring hypersensitivity 
reactions.96,102,103,121,292 The basic principle of this test involves measuring the 
incorporation of radio-labelled thymidine (3H-thymidine) in PBMCs to measure cell 
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division.243,291,293,294 The result in counts per minute (cpm) is expressed as a stimulation 
index (SI). Increased proliferation results in a greater SI value, however high SI values 
are not correlated with clinical severity.121  
1.7.2.3 Flow Cytometry to Study Activated T Cell Subsets 
As previously mentioned, CD69 is a marker present soon after T cell stimulation. 
However, there are others including CD25, CD71, and HLA-DR.121,233–235 Two relevant 
papers use flow cytometry to detect CD69 upregulation after drug stimulation include one 
by Nishio101 and another by Beeler and colleagues.295 Beeler et al. observed that CD69 is 
upregulated more in drug-allergic individuals than in non-allergic individuals and suggest 
CD69 as a promising tool for detecting drug-reactive T cells in peripheral blood.295 In 
addition, CD69 measurement by flow cytometry has been used in other allergies as well, 
including delayed hypersensitivity reactions to iodine contrast media.296 
1.8 Rationale 
My research will attempt to fill the gap that exists in the literature concerning the T cell 
phenotypes of drug hypersensitivity reactions. Currently, there are limited numbers of 
papers that link T cell subsets with different reactions. There are some papers that link 
individual cytokines, chemokines, enzymes, or proteins (see section Immune Mediation 
of DHRs) however there is not a full understanding of the physiology of these reactions. 
There are several “hypotheses” that attempt to explain the pathophysiology of these 
reactions, however there are many unknowns and there is no one mechanism more 
supported than the others.  
Flow cytometry has been used previously to study these reactions, however it has been 
limited in favour of other methods, including ELISA/ELISpot, the LTT, and cloning 
drug-specific T cell subsets. Flow cytometry is beneficial because it allows the detection 
of multiple fluorochromes bound to multiple proteins on the cell surface, which is 
beneficial in staining for both cell type and activation. The overall idea would be to 
confirm that the immune cells are dividing in response to drug stimulation, determine 
which immune cells are activated during this stimulation, and which cytokines are 
secreted as a result. Since certain cytokines are associated with specific T cell subsets, 
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these secreted cytokines can be used to determine which T cells could be involved in the 
reactions. Consenting participants with confirmed reactions to sulfamethoxazole and 
beta-lactam antibiotics will be asked to participate in this study. SMX and AMX were 
chosen due how they are both commonly associated with DHRs. The ultimate goal is to 
conduct a comprehensive study of the phenotypes of T cell involvement in specific 
clinical presentations of hypersensitivity reactions to various medications. 
1.8.1 Hypothesis 
I hypothesize that differences in activated peripheral T cell subsets and types of 
mediators released produce different clinical phenotypes of drug hypersensitivity 
reactions to sulphnamides and beta-lactam antibiotics.  
1.8.2 Aims 
In this study, my aim was to study and characterize lymphocytes isolated from peripheral 
blood samples from patients with clinical presentations suggestive of delayed-type drug 
hypersensitivity reactions and compare with drug tolerant controls. To do this, I will use 
different techniques such as scintillation counting, flow cytometry, and multiplex bead-
based assays to measure in vitro PBMC and T cell proliferation. I will use radiolabeled 
thymidine incorporation to measure proliferation in response to treatment, flow 
cytometry to determine activated T cell subsets, and Luminex, a bead-based detection 
assay, to analyze cytokine release of T cell subsets. 
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Chapter 2  
2 Experimental Design and Methods 
This research project is part of a larger drug safety project being conducted in the Rieder 
laboratory. The first stage of the project, being performed by another lab member, is to 
learn about the symptoms that patients with drug hypersensitivity have by completing a 
detailed survey to determine the extent and nature of the reaction. Another component of 
the project is to extract DNA from the isolated PBMCs and study markers in each 
subgroup of patients exhibiting different clinical presentations of drug hypersensitivity. 
My portion of the project was to characterize the T cell phenotypes of the different 
clinical presentations of drug hypersensitivity reactions. To date, while there has been 
some research into the different types of T cells involved in certain DHRs, much is still 
unknown. To do this, I obtained venous blood samples from patients and controls and 
isolated and characterized isolated PBMCs/T cells. A methods schematic is detailed in 
Figure 2-1. Research ethics had been previously obtained by Dr. Rieder’s laboratory for 
this project (REB # 1118833E).  
 
Figure 2-2-1: Schematic of methods used 
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2.1 General Methods 
2.1.1 PBMC Isolation 
We isolated PBMCs from whole blood using density gradient separation. First, 
approximately 15 ml of blood was diluted 1:1 in 1× phosphate buffered saline (PBS, 
protein-free, pH 7.2, Gibco by Life Technologies, catalogue no. 20012-027). Then, 30 ml 
of the blood + PBS 1:1 mixture was carefully layered over 15 ml of Ficoll Histopaque-
1077 (Sigma, catalogue no. 10771), and centrifuged for 20 minutes (increased to 30 
minutes if blood was drawn the day before) at 1500 rpm. The grey PBMC layer was 
transferred to new 50ml tubes by serological pipette, and washed twice, each time with a 
full tube (50 ml) of PBS and centrifuged at 1600 rpm for 10 minutes. The PBMCs were 
diluted to 5 × 106 cells/ml in Roswell Park Memorial Institute (RPMI) medium (+ L-
glutamine, 1640 1×, catalogue no. 11875-093) supplemented with 10% human AB serum 
(Sigma, catalogue no. H3667) by manual counting with a hemocytometer. 
2.1.2 Preparing Universal Mitogen Stimulation Plates 
To prepare for stimulation, anti-CD3 antibody (Ultra-LEAF purified antihuman CD3 
antibody, clone OKT3, Biolegend, catalogue no. 317325) was coated on the bottom of a 
U-bottom 96-well plate. To the required number of labelled wells, 2 µl anti-CD3 
antibody (at 1mg/ml) and 98 µl of 1× protein-free PBS are added. The plate was wrapped 
in parafilm and left in the fridge (4 °C) overnight. The following day, the plates were 
centrifuged at 1600 rpm for 10 minutes and the supernatant decanted before PBMCs or T 
cells were added into coated wells. 
2.1.3 Assessing Proliferation by Scintillation Counting 
For scintillation counting, the stimulants included anti-CD3, the drug the patient was 
sensitive to, or culture media (RPMI + 10% human AB serum) as an unstimulated 
control. The PBMCs were incubated with the stimulant, drug, or media for 54 hrs and 4 
days in an incubator at 37 °C and 5% CO2. Sixteen hours before harvesting the plates, 1 
µCi of tritiated thymidine (Thymidine, [methyl-3H], Perkin Elmer, catalogue no. 
NET027005MC, lot no. 201510) was diluted in culture media 1:10, then 10 µl of the 
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tritiated thymidine/media mixture was added to both stimulated (by anti-CD3 and drug) 
and unstimulated PBMCs (alternatively, the 3H-thymidine is diluted 1:25 in media, and 
added to all wells with a repeater pipettor if number of wells is very high). The PBMCs 
were then washed and harvested using a cell harvester (Tomtec, Hamden, CT), and the 
thymidine incorporation is assessed using a MicroBeta counter (Micro Beta Jet, Perkin 
Elmer1450 LSC & Luminescence Counter). Proliferation is assessed by calculating the 
stimulation index (SI), by subtracting average background counts per minute (cpm) from 
the average cpm of each type of sample, then dividing by the average of the unstimulated 
wells.  
2.1.4 Assessing Proliferation of T Cell Subsets by Flow Cytometry 
2.1.4.1 Flow Cytometry Protocol 
PBMCs were seeded into a U-bottom 96-well plate, then stimulated in vitro with the drug 
the patient had a reaction to (ie. AMX or SMX) at the test concentrations, or stimulated 
with anti-CD3 (see § Preparing Universal Mitogen and Stimulation Plates section), a T 
cell mitogen, as a controlled comparison. The cells were incubated for 54 hrs in an 
incubator at 37 °C and 5% CO2.  
The PBMCs were stained with eBioscience Fixable Viability Dye eFluor 506 
(ThermoFisher Scientific, catalogue no. 65-0866-14) according to manufacturer’s 
instructions to identify dead cells in the sample. The cells were also stained with 
allophycocyanin (APC) mouse antihuman CD3 (BD Pharmingen, clone UCHT1, 
catalogue no. 561810) to identify all T cells, brilliant violet 421 (BV421) mouse 
antihuman CD8 (BD Horizon, clone RPA-T8, catalogue no. 562429) to identify cytotoxic 
T cells, phycoerythrin (PE) mouse antihuman CD4 (BD Pharmingen, clone RPA-T4, 
catalogue no. 561843) to identify helper T cells, phycoerythrin-cyanine 5 (PE-Cy5) 
antihuman CD69 (eBioscience, clone FN50, catalogue no. 25-0699-41), all according to 
manufacturer’s instructions, to identify activated T cells. Single stain controls were 
performed with Invitrogen UltraComp eBeads (ThermoFisher Scientific, catalogue no. 
01-2222-42). All cells were fixed by resuspension in 100 µl of 4% paraformaldehyde 
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solution and 200 μl of 1× PBS + 3% FBS (foetal bovine serum) prior to flow cytometry 
analysis. Samples were analyzed within 4 days post-fixing. 
2.1.4.2 Flow Cytometry Specifications 
All flow cytometry experiments were performed at the London Regional Flow Cytometry 
Facility at Robarts Research Institute, Western University. The PBMCs were analyzed on 
a Becton Dickinson LSR II analysis cytometer (BD Biosciences), using FACSDiVa 
software (version 8.0.1). The flow cytometer is equipped with a 50 mW Coherent Cube 
402 nm violet diode laser, a 2 mW Coherent Sapphire state 488 nm blue laser, a 50 mW 
Coherent Compass 561 nm solid-state yellow-green laser, and a 40 mW Coherent Cube 
640 nm red diode laser. 
The violet laser trigon was used to detect Brilliant Violet 421 (detector C, with a 450/50 
bandpass (bp) filter and no longpass (lp) mirror), and to detect the fixable viability dye 
(detector B, 525/50 bp, 505 lp). The yellow-green laser octagon was used to detect PE 
(detector E, 582/15 bp), and PE-Cy7 (detector A, 78/60 bp, 755 lp). The red laser trigon 
was used to detect APC (detector C, 670/30 bp). 
2.1.4.3 FlowJo Gating Procedure 
Data was analyzed using FlowJo software (FlowJo, LLC). On FlowJo, the gates were set 
using FMO (fluorescence minus one) controls on the fully stained samples. First, forward 
scatter area (FSC-A) was gated against the aqua viability dye to gate only live cells. Side 
scatter height (SSC-H) was gated against side scatter width (SSC-W), and forward scatter 
height against forward scatter width to gate single cells. Then, CD3 APC was compared 
against SSC-A to gate CD3+ and CD3- stained cells. Within the CD3- population, CD69 
PE-Cy7 was compared against SSC-A to identify with CD3-CD69+ population. Within 
the CD3+ lymphocyte population, CD4 PE was compared against SSC-A to determine the 
CD4+ population. Within this gate, CD69 was compared against SSC to determine the 
CD4+CD69+ population. From the CD3+ population, CD8 was compared against SSC-A 
to determine the CD8+ population. Within this population, CD69 was compared against 
SSC-A to determine the CD8+CD69+ population. 
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2.1.5 Cryopreservation of PBMCs and T Cells 
This method has been adapted from the Canadian Healthy Infant Longitudinal 
Development (CHILD) Study, from their 8-Year Biological Samples Collection and 
Processing SOP, 23 July 2018 edition.297 Once all appropriate experiments were prepared 
with the patient PBMCs and T cells, aliquots of cells were frozen under liquid nitrogen 
for future analysis.  
The 2× freezing medium was prepared by combining 15 ml of heat-inactivated fetal 
bovine serum (FBS), 15 ml of RPMI 1640, and 10 ml of dimethyl sulfoxide (DMSO), 
aliquoted in 3 ml volumes and remainder stored at -20 °C. 
Both T cells and PBMCs are resuspended at 1 × 107 cells/ml in RPMI 1640 + FBS 1:1. 
Labelled cryovials were placed on ice, then 500 μl of PBMC or T cell suspension were 
added to each tube. Then we added 500 µl of 2× freezing medium to each cryovial while 
on ice. 
The Mr Frosty (Nalgene, Thermo Scientific, USA) was prepared by removing the insert 
and adding 250 ml of isopropanol to the container. The vial holder was replaced into the 
container. The isopropanol was changed after every fifth use. The Mr. Frosty was placed 
into the fridge at 4 C more than four hours before it is required. The PBMC and T cell 
aliquots were placed into the Mr. Frosty and then into the -80 °C freezer for 4 to 24 hours 
(typically overnight), and then the samples were placed into the liquid nitrogen long term 
storage tank into a known and recorded location. 
2.2 Specific Experimental Procedures and Methods 
2.2.1 Assessing Highest CD69 Expression on T Cells 
I explored the length of the incubation for incubating isolated PBMCs with the culprit 
drug or universal mitogen (anti-CD3). This experiment was based off of a study by 
Beeler et al.295 The evening before isolating the PBMCs and plating the cells, I coated 21 
wells (three wells per timepoint for five timepoints, five FMO wells, one viability dye 
compensation control well) of a U-bottom 96-well plate with anti-CD3 and PBS, as 
previously described (see § Preparing Universal Mitogen and Stimulation Plates) and 
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allowed the plate to rest in the fridge. I started with 15 ml healthy volunteer blood and 
LEAF anti-CD3 as the universal mitogen. I did not have access to hypersensitive patient 
samples, so a drug stimulant was not used. I isolated the PBMCs from the 15 ml of blood 
(as described in § PBMC Isolation), suspended the PBMCs in 10 ml of RPMI with 1´ 
penicillin/streptomycin and 10% human AB serum, counted the cells in a hemacytometer, 
and adjusted the concentration to 5 ´ 106 cells/ml. The plate with anti-CD3 coated wells 
was centrifuged at 1600 rpm for 10 minutes, then I decanted the supernatant and added 
200 ul of PBMC suspension to 21 coated wells and 12 uncoated wells. Every 18 hours I 
harvested three wells of anti-CD3 stimulated and three unstimulated samples for flow 
cytometry and stained with Aqua Viability Dye, CD3 APC, CD4 PE, CD8 BV421, and 
CD69 PE-Cy7 (as described in § Assessing Proliferation of T Cell Subsets by Flow 
Cytometry subsection A, Flow Cytometry Protocol) for a total of five timepoints. After 
staining, the PBMCs were suspended in 100 µl 1 × PBS + 3% FBS and 100 µl 4% 
paraformaldehyde for flow cytometer acquisition. Single stain compensation controls for 
CD3 APC, CD4 PE, CD8 BV421, and CD69 PE-Cy7 were made fresh using comp beads. 
In total, 15 stimulated timepoint samples, 15 unstimulated timepoint samples, five FMO 
samples, and five single stain compensation controls were analyzed. To analyze the data, 
the unstimulated values were subtracted from the stimulated values in an attempt to 
normalize.  
2.2.2 Testing Healthy Cells with Concentrations of SMX-HA and 
SMX Parent Drug 
The purpose of this experiment was to determine the magnitude of cell death caused by 
different concentrations of either sulfamethoxazole hydroxylamine reactive metabolite 
(SMX-HA) or sulfamethoxazole parent drug (SMX). As SMX-HA is more reactive than 
SMX and can cause cell death, we used both drugs to determine the best one to use in this 
experiment. The evening before the experiment, I coated nine wells of a U-bottom 96-
well plate with anti-CD3 (see § Preparing Universal Mitogen and Stimulation Plates) for 
flow cytometry. 
I isolated PBMCs from approximately 15 ml of healthy volunteer blood and suspended 
the PBMCs in 10 ml of RPMI 1640 supplemented with 10% human AB serum. Using a 
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hemacytometer, the PBMCs were counted and the concentration was adjusted to 5 × 106 
cells/ml. The 96-well plate was centrifuged at 1600 rpm for 10 minutes, and the 
supernatant decanted. I added 100 µl of healthy PBMCs to each of the anti-CD3 coated 
wells and to 21 non-coated wells. Of the nine anti-CD3 coated wells, five of the 
stimulated wells were for FMOs, one of the stimulated wells was for the viability dye 
single stain control, three stimulated wells were for control wells – to these wells I added 
100 µl RPMI 1640 + 10% human AB serum. I also added 100 µl of media to three 
unstimulated wells to be stained with the full panel of fluorescent antibodies. For 
unstimulated wells, media was added because no drugs were required, but the final 
volume required was 200 µl. Sulfamethoxazole parent drug was added to nine 
unstimulated wells in 200 µM, 100 µM, and 50 µM concentrations, three wells each. 
Sulfamethoxazole hydroxylamine was added to nine unstimulated wells in 100 µM, 50 
µM, and 25 µM concentrations, three wells each. The plate was incubated for 54 hrs. The 
cells were harvested into flow cytometry tubes, stained with viability dye, CD3 APC, 
CD4 PE, CD8 BV421, and CD69 PE-Cy7, acquired on the LSR II flow cytometer with 
FACS Diva and analyzed using FlowJo (see § Assessing Proliferation of T Cell Subsets 
by Flow Cytometry). Once a concentration of SMX-HA was found to potentially cause 
cell death, two more healthy control participants were tested with anti-CD3 and the 
concentration previously found to reduce cell viability, to ensure results were consistent. 
2.2.3 Processing Patient Samples 
2.2.3.1 Recruiting Participants 
Subjects were recruited from patients seen at Dr. Rieder’s Drug Safety Clinic at London 
Health Science Centre, Victoria Hospital in London, Ontario. Prospective patients were 
determined from a database of Dr. Rieder’s DHR patients, on the basis of having 
previously been tested by LTA (Lymphocyte Toxicity Assay) for a T-cell mediated drug 
hypersensitivity reaction to either sulfamethoxazole or beta-lactam antibiotics. The LTA 
testing was either being conducted simultaneously for patients with a high likelihood 
based on clinical history, or one to eight years previously. For these participants, blood 
was drawn either at Robarts Research Institute, London, Ontario by Dr. Rieder, or at 
University Hospital, in London, Ontario by phlebotomy staff. Inclusion criteria were that 
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they had a positive LTA test, or they were in the process of being tested and their clinical 
history strongly suggested DHR, and had a recorded rash or skin condition attributed to 
drug exposure. Patients who were very likely to have had a DHR based on history alone 
who were referred to LTA testing. For these participants, blood was drawn at the same 
time as the blood for the LTA testing. I called previous or current patients and asked if 
they would be willing to provide a sample for the study, or to add one 1-2 tubes of blood 
to their LTA testing. The details of the experiment and their privacy were discussed over 
the phone, and they were sent a copy of the Letter of Information (LOI) with the consent 
forms either in advance or in person before the appointment. Participants were given a 
$10 Tim Horton’s gift card for their time and their sample. 
2.2.3.2 Receipt and Preparation of Participant Samples 
After patient samples were received, a control sample (~15 ml) of blood was drawn from 
a healthy, consenting volunteer. Typically one control was used per one DHR participant. 
The control was ideally someone who has taken the drug the patient participant has a 
hypersensitivity to but did not have an adverse response, or someone who has served as a 
control in previous LTA tests but consistently tests negatively. One control sample and 
one patient sample were analyzed at the same time. Depending on availability of samples, 
the samples were processed and PBMCs were isolated either the same day or the next day 
(see § PBMC Isolation). If PBMCs were isolated the day after blood was collected, an 
extra 10 minutes was added to the centrifugation at the Ficoll separation step for those 
samples only. PBMCs were re-suspended after isolation to 5 × 106 cells/ml in RPMI + 
10% human AB serum. If testing only one drug, 15 ml was prepared, or 20ml for two 
drugs, to accommodate additional wells. 
2.2.3.3 Preparing SMX and AMX to study Activation 
To stimulate PBMCs, four different concentrations were made from analytical grade 
powder for each drug, AMX and SMX. Two serial dilution charts (see Figure 2-2 and 
Figure 2-3) were used for each patient to make the appropriate dilutions. Drugs were 
diluted 1:1 with 100 µL of PBMC suspension to achieve final concentrations of AMX 
1000 µM, 500 µM, 100 µM, and 10 µM; SMX 800 µM, 400 µM, 200 µM, and 100 µM. 
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All drug preparations were made fresh the day of plating, and either used immediately or 
kept in the dark until required (usually only maximum of 1 hr). 
 
Figure 2-2: Serial dilution chart for amoxicillin	
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Figure 2-3: Serial dilution chart for sulfamethoxazole	
2.2.3.4 Assessing Proliferation by Scintillation Counting 
The evening before the PBMCs were plated onto 96-well plates, I made the appropriate 
number of anti-CD3 coated plates. Which plates were made depended on which 
experiments would be conducted the next day – this was important because cell 
harvesting and scintillation counting for proliferation testing could not be performed on a 
weekend due to equipment availability, so the 54 hrs and 4 days scintillation counting 
plates were coated strategically to avoid this. For each control and participant plate at 
both time points, I coated four wells. The following day, 100 ul patient and control 
PBMCs at 5 × 106 cells/ml in RPMI + 10% human AB serum were plated with either 100 
ul of media (RPMI + 10% human AB serum as negative control), anti-CD3 with added 
media to bring volume up to 200 µl, or the 100 µl of the four different concentrations of 
the appropriate drug. Four wells of each condition were plated. At 16 hours before 
harvesting, 1 µCi of 3H-thymidine was added to each well (see § Assessing Proliferation 
by Scintillation Counting for details). See Figure 2-4 for a sample plate layout. 
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Figure 2-4: Sample scintillation counting plate layout 
If two drugs were plated, the wells occupied rows A-H columns 8-11. One plate is made 
for control PBMCs, a second plate is made for patient PBMCs, and two plates are 
processed for each 54 hrs and 4 days incubation period. 
2.2.3.5 Flow Cytometry for Activated CD4 and CD8 T Cells 
The flow cytometry plate cells were harvested into flow cytometry tubes using a plastic 
transfer pipette, and PBS to rinse the wells to ensure all cells were transferred into the 
tubes. The cells were washed with PBS and centrifuged at 1600 rpm for 10 minutes. The 
supernatant was removed by pipette and the cell pellet resuspended in 1 ml of PBS. To all 
tubes except the viability dye FMO, I added 1 μl of viability dye. The anti-CD3 
stimulated PBMCs were stained with one test each of CD3 APC, CD4 PE, CD8 BV421, 
and CD69 PE-Cy7 (see § Assessing Proliferation of T Cell Subsets by Flow Cytometry 
subsection A, Flow Cytometry Protocol, for details) while the FMO tubes were stained 
appropriately (see Figure 2-5 for a sample flow cytometry staining panel for patient 
samples). PBMCs were washed twice with 1 × PBS + 3% FBS, and resuspended in 100 
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ul 4% paraformaldehyde, to fix the cells, and 200 µl of 1× PBS + 3% FBS. The 
experiment was acquired on the LSR II as soon as possible after staining (within 2-3 
days, depending on availability of the cytometer for a 3-hour time slot). 
 
Figure 2-5: Sample flow cytometry staining panel for patient and control samples 
2.2.3.6 Assessing Cytokine Release 
Isolated PBMCs and T cells from both control and patient samples were stimulated with 
anti-CD3, the drug concentrations, and culture media (unstimulated) in duplicate. The 
evening before plating, two anti-CD3 plates are prepared (see § Preparing Universal 
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Mitogen Stimulation Plates). T cells were only isolated and plated if there were enough 
cells remaining from the patient and control samples to justify isolating them without 
compromising cell numbers for other experiments. The plates were divided into two (one 
half for PBMCs, one half for T cells), and two wells are coated in each half (4 wells total 
per plate). PBMCs were plated in duplicate at 5 × 106 cells/ml in RPMI + 10% human 
AB serum with either media (control), anti-CD3, or the four concentrations of either drug 
(AMX or SMX). After a 3-day incubation at 37 °C and 5% CO2, the supernatant was 
removed from samples, stored in labelled Eppendorf 2 ml tubes, and frozen at -80 C until 
analysis could be completed.  
Stimulated DHS and control participant PBMCs were subjected to Luminex analysis. 
Since the AMX data was more promising, only AMX participants and controls were 
included in the Luminex analysis. Control and DHR 006 participants were not analyzed 
due to heavy RBC contamination in DHS006 samples.  
A custom Luminex kit was ordered from Bio-Rad (Hercules, CA), specific for analytes 
IFN-y, IL-9, IL-22, IL-17A, and IL-13 (PO # 0222850). The analysis was performed 
according to manufacturer’s instructions. The beads were diluted as instructed by the 
manufacturer. Since it was a custom kit, some beads were 2× as concentrated as others, 
so they were diluted appropriately. A plate layout was generated (see Figure 2-6), with all 
blanks, standards, and samples analyzed in duplicate. A standard curve was generated for 
the beads. Bio-Rad suggests neat to 1:10 dilution, but since some of the standards had 
such a high starting concentration, we chose neat to 1:12 dilution to accommodate this, as 
well as to fill up the plate.  
Frozen supernatants were thawed over ice and centrifuged for 3 minutes at 12000 rpm to 
pellet any debris. Since the supernatants were composed of culture media (with added 
protein), no BSA was added to the samples. Then 50 µl of the diluted beads were added 
to each well and washed two times with wash buffer and the magnetic plate. Then, 50 µl 
of samples, standards, and blank were added to each well, covered, and incubated with 
shaking for 1 hr. With 10 mins remaining in the incubation, the antibodies were diluted to 
1× according to instructions. The plate was washed three times with wash buffer and the 
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magnetic plate, then 25 µl of detection antibodies was added to each well. The plate was 
covered and incubated with shaking for 30 mins. With 10 mins remaining in the 
incubation, the streptavidin-PE (SA-PE) was prepared. The plate was washed three times 
with wash buffer and the magnetic plate, then 50 µl of diluted SA-PE was added to each 
well. The plate was covered and incubated for 10 mins. A final round of three washes 
was performed, and each well was resuspended in 125 µl of assay buffer. The plate was 
covered and placed on the shaker until analysis.  
A Bio-Plex 200 readout system (Bio-Rad) was used to analyze the cytokines. This system 
uses Luminex ® xMAP fluorescent bead-based technology (Luminex Corporation, 
Austin, TX). Cytokine levels (pg/ml) were automatically calculated from standard curves, 
generated by the Bio-Plex Manager software (v. 6.1, Bio-Rad, Hercules, CA). 
 
Figure 2-6: Luminex sample plate layout	
S1-S12: standard bead dilutions, D4-D8: DHS participant, C4-C8: control participant. All 
samples were supernatants of PBMCs incubated with AMX.  
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2.3 Statistical Methods 
An ANOVA can be used to test three or more groups without inflating the alpha value, 
which would be the case with multiple comparisons.298 Repeated measures ANOVA 
(rANOVA) was used to perform many of the statistical analyses as the same participants 
were tested repeatedly across the dependent variable. This is beneficial as it reduces the 
error.  
However, one important aspect of rANOVA is sphericity. When sphericity is violated, 
the test becomes too liberal (increases Type I error rate) and therefore might indicate a 
significant result when it should actually be not significant. As a result, there are some 
tests that correct the rANOVA by increasing p to make the test more conservative. We 
chose to analyze sphericity-violated rANOVAs with the Greenhouse-Geisser correction. 
A previous analysis by Muller and Barton (1989) supports the use of the Greenhouse-
Geisser correction (over Huynh-Feldt) due to acceptably controlling for Type I error 
while also maximizing power.299  
While we did use statistical methods when appropriate, it is important to note that the N 
of the study was relatively small for certain tests, it would be prudent to increase the 
number of participants in the study to increase the power.  
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Chapter 3  
3 Experimental Set 1 
It has been previously shown that T cells appear to be key mediators of DHRs.53,54,96–104 
While it is not fully understood how they are involved, it is thought that they, as well as 
their mediators, are primarily responsible for the immunological pathogenesis of these 
reactions. In addition, CD69 has been previously shown to be an activation marker that is 
expressed on the T cell surface rapidly after activation.295 However, CD69 does not 
remain on the cell surface indefinitely, and its quantity can change after activation. For 
our own purposes, it was important to do our own tests to observe what methods would 
work for us. This includes which metabolites to use, length of incubation time, percent of 
CD69 expression.  
3.1 Using SMX Yields more Live Cells than SMX-HA 
In addition to sulfamethoxazole (SMX) parent drug, there are two intermediates that can 
also cause a reaction, however they differed in their toxicity. To decide which form of 
SMX we would use, I tested concentrations of SMX and sulfamethoxazole 
hydroxylamine (SMX-HA). PBMCs from one volunteer donor were incubated with 
culture media (unstimulated), 500µM, 100µM, and 200µM SMX, and 25µM, 50µM, and 
100µM SMX-HA, and analyzed by flow cytometry for the percentage of live cells 
remaining after incubation (Figure 3-1).  
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Figure 3-1: Percentage of live cells after PBMCs from a healthy control were 
incubated with either culture media, SMX, or SMX-HA for 54 hours 
Concentrations of 50µM, 100µM, and 200µM SMX; 25µM, 50µM, and 100µM SMX-
HA for 54 hrs. N = 1.  
Without statistical analysis, given the small sample size (N=1), there do not seem to be 
any differences between the SMX-stimulated samples. However, there was a decrease in 
cell viability when the PBMCs were incubated with 100µM SMX-HA. To confirm, this 
concentration was repeated with two additional healthy controls, increasing the sample 
size to 3 (Figure 3-2). A Student’s t test confirmed that 100µM SMX-HA significantly 
reduces cell viability (p = 0.0017).  
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Figure 3-2: Percentage of live cells remaining after PBMCs from three controls were 
incubated with 100uM SMX-HA for 54 hrs 
The PBMCs incubated with 100µM SMX-HA have a significantly lower number of live 
cells remaining after incubation compared with unstimulated PBMCs with media alone 
(student’s t test, one-way, p = 0.0017). N = 3, ± SEM. 
3.2 Length of Incubation affects Viability of PBMCs  
To determine the best length of time for incubating PBMCs with a stimulant, PBMCs 
were incubated with plate-bound anti-CD3 for five intervals of 18 hours, in an 
experiment similar to Beeler et al.295 First, the percent of live PBMCs remaining after 
incubation was analyzed every 18 hours by flow cytometry (Figure 3-3). There was a 
gradual decrease in viability as the timepoints increased. At 90 hrs, viability decreased to 
an average of approximately 50% viability. Our chosen timepoint of 54 hrs did not differ 
significantly from 18hrs.  
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Figure 3-3: The percent of live cells remaining after PBMCs were incubated with 
plate-bound anti-CD3 at 18 hr intervals for 90 hrs 
A repeated measures ANOVA was conducted to determine if any time intervals were 
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was 
violated, therefore the Greenhouse-Geisser correction was used. There was a significant 
effect of time on number of live PBMCs remaining. F(1.164, 2.328) = 25.351, p = 0.027. 
N = 3, ± SEM. 
3.3 Percent of T Cells expressing CD69 during Incubation 
PBMCs were also analyzed for percent CD69 expression and MFI of CD69 across CD3+, 
CD3+CD4+, and CD3+CD8+ cell types. Unstimulated percent of CD69 expression 
values were subtracted from anti-CD3 stimulated values. With the CD3+ percent CD69 
and MFI (Figures 3-4 and 3-5), there were no significant timepoints, however the overall 
appearance of the data can be described. With both the percent CD69 and the MFI of 
CD69, 18, 54, and 72 hr timepoints appeared to be the highest. With CD3+CD4+ percent 
CD69 and MFI (Figures 3-6 and 3-7), the trends were different, but again not significant. 
With the percent CD69 (Figure 3-6), there seemed to be an overall decrease in percent 
CD69 expression from the 18 hr to the 90 hr timepoint. With the MFI of CD69 (Figure 3-
7), the 18 hr, 54 hr, and 72 hr timepoints were the highest, however the values were more 
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variable. With CD3+CD8+ percent CD69 and MFI (Figures 3-8 and 3-9), while also 
providing no significant timepoints. 
While there were no significant differences between timepoints (that either caused a 
significantly higher or lower cell viability), the timepoint 54 hrs was chosen for the 
participant experiments. 
 
Figure 3-4: Percentage of CD3+ T cells expressing CD69, assessed by flow 
cytometry, after PBMCs from three healthy control participants were incubated 
with anti-CD3 for 90 hrs for intervals of 18 hrs 
A repeated measures ANOVA was conducted to determine if any time intervals were 
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was 
violated, therefore the Greenhouse-Geisser correction was used. There was no significant 
effect of time on percent CD69 expression on CD3+ T cells. F(1.041, 2.081) = 1.494, p = 
0.346. N = 3, ± SEM. 
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Figure 3-5: MFI of CD69 expressing CD3+ T cells, assessed by flow cytometry,  
after PBMCs from three control participants were incubated with anti-CD3 for 90 
hrs for intervals of 18 hrs 
A repeated measures ANOVA was conducted to determine if any time intervals were 
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was 
violated, therefore the Greenhouse-Geisser correction was used. There was no significant 
effect of time on the MFI of CD69 expression on CD3+ T cells. F(1.072, 2.145) = 0.495, 
p = 0.563. N = 3, ± SEM. 
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Figure 3-6: Percentage of CD3+CD4+ T cells expressing CD69, assessed by flow 
cytometry, after PBMCs from three healthy control participants were incubated 
with anti-CD3 for 90 hrs for intervals of 18 hrs 
A repeated measures ANOVA was conducted to determine if any time intervals were 
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was 
violated, therefore the Greenhouse-Geisser correction was used. There was no significant 
effect of time on % CD69 expression on CD3+CD4+ T cells. F(1.087, 2.173) = 3.660, p = 
0.188. N = 3, ± SEM. 
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Figure 3-7: The MFI of CD69 expressing CD3+CD4+ T cells, assessed by flow 
cytometry, after PBMCs from three healthy control participants were incubated 
with anti-CD3 for 90 hrs for intervals of 18 hrs 
A repeated measures ANOVA was conducted to determine if any time intervals were 
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was 
violated, therefore the Greenhouse-Geisser correction was used. There was no significant 
effect of time on the MFI of CD69 expression on CD3+CD4+ T cells. F(1.072, 2.144) = 
0.362, p = 0.619. N = 3, ± SEM. 
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Figure 3-8: Percentage of CD3+CD8+ T cells expressing CD69, assessed by flow 
cytometry, after PBMCs were incubated with anti-CD3 for 90 hrs for intervals of 18 
hrs 
A repeated measures ANOVA was conducted to determine if any time intervals were 
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was 
violated, therefore the Greenhouse-Geisser correction was used. There was no significant 
effect of time on percent CD69 expression on CD3+CD8+ T cells. F(1.689, 3.378) = 
1.735, p = 0.296. N = 3, ± SEM. 
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Figure 3-9: The MFI of CD69 expressing CD3+CD8+ T cells, assessed by flow 
cytometry, after PBMCs from three control participants were incubated with anti-
CD3 for 90 hrs for intervals of 18 hrs 
A repeated measures ANOVA was conducted to determine if any time intervals were 
significant. Mauchly’s Test of Sphericity indicated that the assumption of sphericity was 
violated, therefore the Greenhouse-Geisser correction was used. There was no significant 
effect of time on the MFI of CD69 expression on CD3+CD8+ T cells. F(1.216, 2.432) = 
0.744, p = 0.493s. N = 3, ± SEM. 
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Chapter 4  
4 Experimental Set 2 
Both sulfamethoxazole (SMX) and beta-lactam antibiotics (for example, penicillin) have 
been previously shown to elicit DHRs.137,258,259,261 In addition, both are commonly 
prescribed antibiotics. The lymphocyte transformation test (LTT) is an effective 
diagnostic test for delayed type DHRs.96,102,103,121,292 Flow cytometry has been previously 
used to detect CD69 upregulation after drug stimulation.101,295,296 While its use in delayed 
type DHRs has been limited, it is a promising way to detect cellular response using 
surface proteins. In addition, differences in cytokine secretion, which can be analyzed in 
several different ways, are an effective way to study DHRs.137,186,300  The goal was to 
determine if there were patterns among the clinical presentations of people previously 
diagnosed with DHRs to SMX and AMX.  
4.1 Description of Participant Population 
The mean age of DHR participants (Table 4-1) was 50.5 years, with a standard deviation 
of approximately 19.1 years, and the ratio of female to male participants was 7:1. The 
mean age of the control participants (Table 4-2) was 31.125 years, with a standard 
deviation of 13.3, and a female to male participant ratio of 4:4. Student’s t-test confirmed 
that there was a significant difference in average age between the two participant 
populations (Student’s t-test, one-tailed, p = 0.017). All control AMX participants had 
previously taken the drug, while the control participants either had never taken 
sulfamethoxazole or had no recollection.  
It is important to note that within the SMX participants, of the four oldest participants, 
three were DHS participants. Within the AMX participants, of the four oldest, again three 
were DHS.  
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Table 4-1: List of participants with drug allergies that took part in the study, 
recruited from Dr. Michael Rieder’s drug allergy clinic at London Health Sciences 
Centre, in London, Ontario, Canada 
Participant 
identifier 
Age as of 
collection date 
Listed 
sex 
Drug 
tested 
History/symptoms with drug 
DHS001 52 F SMX Rash (unspecified) 
DHS002 72 F SMX No recollection 
DHS003 48 F SMX Oral blistering (SJS?) 
DHS004 51 F AMX Serum-sickness like 
DHS005 22 F AMX Morbilliform rash 
DHS006 63 M AMX SJS 
DHS007 24 F AMX Rash (unspecified) 
DHS008 68 F AMX and 
SMX 
Pruritic rash, requiring 
hospitalization 
 
Table 4-2: List of control participants that participated in the study, recruited from 
Western University, in London, Ontario, Canada 
Participant 
identifier 
Age as of 
collection date 
Listed 
sex 
Drug 
tested 
History/symptoms with drug 
C001 27 F SMX No recollection 
C002 21 F SMX Never taken sulfa 
C003 60 F SMX Never taken sulfa 
C004 41 M AMX Taken before, no adverse 
reactions 
C005 23 M AMX Taken before, no adverse 
reactions 
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C006 24 F AMX Taken before, no adverse 
reactions 
C007 24 M AMX Taken before, no adverse 
reactions 
C008 26 M AMX and 
SMX 
Taken AMX before, unsure 
about SMX 
4.2 Scintillation Counting Results 
Control and SMX/AMX participant PBMCs were also incubated with the drug and 3H-
thymidine to determine if the drug stimulated DHS participant PBMCs, resulting in the 
proliferation of cells and a high stimulation index (SI). SI is a ratio of unstimulated 
PBMCs to drug stimulated PBMCs. Typically, an SI of 2 is required to say that the 
PBMCs are responding to the drug in vitro.  
4.2.1 Scintillation Counting Results from SMX-Hypersensitive 
Participants 
When control and DHR participant PBMCs were incubated with SMX for 54 hrs, there 
was no significant change in SI (Figure 4-1), and there was no trend observed for either 
control or DHR participants (ie. no overall increase or decrease). There were no SIs at or 
greater than 2, therefore none shows a positive proliferative response to the drug 
treatment.  
Control and DHR participant PBMCs were also incubated with SMX for 4 days (Figure 
4-2). Again, none of the concentrations of SMX were found to be significant. None of the 
participants had a SI greater than 1.2.  
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Figure 4-1: SI of control and DHS participants after incubation with SMX for 54 
hrs 
A repeated measures ANOVA was conducted to determine if the concentration of SMX 
had an effect on the proliferation of control and DHS PBMCs. Mauchly’s test of 
sphericity was not significant (p = 0.263), therefore the assumption was met and a 
Greenhouse-Geisser correction was not used. F(4, 24) = 0.443, p = 0.776. N(control) = 4 
and N(DHR) = 4, ± SEM. 
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Figure 4-2: SI of control and DHS participants after incubation with SMX for 4 
days 
A repeated measures ANOVA was conducted to determine if the concentration of SMX 
had an effect on the proliferation of control and DHS PBMCs. Mauchly’s test of 
sphericity was not significant (p = 0.468), therefore the assumption was met and a 
Greenhouse-Geisser correction was not used. F(4, 24) = 3.234, p = 0.029. N(control) = 4 
and N(DHR) = 4, ± SEM. 
4.2.2 Scintillation Counting Results from AMX-Hypersensitive 
Participants 
In addition to SMX, AMX participants were also recruited. Participant PBMCs were 
incubated with AMX for 54 hrs (Figure 4-3). No participant had a SI greater than 1.2, and 
no significant differences between control and DHR participant or unstimulated and drug 
concentration were found. When incubated with AMX for four days, there were no 
significant differences between control and DHR participant, or between unstimulated 
and drug stimulated (Figure 4-4).  
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Figure 4-3: SI of control and DHS participants after incubation with AMX for 54 
hrs 
A repeated measures ANOVA was conducted to determine if the concentration of SMX 
had an effect on the proliferation of control and DHS PBMCs. Mauchly’s test of 
sphericity was not significant (p = 0.606), therefore the assumption was met and a 
Greenhouse-Geisser correction was not used. F(4, 32) = 1.457, p = 0.238. N(control) = 4 
and N(DHR) = 4, ± SEM. 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
10 100 500 1000
Media + PBMCs AMX concentration (uM)
St
im
ul
at
io
n 
In
de
x
Control DHS
60 
 
 
Figure 4-4: SI of control and DHS participants after incubation with AMX for 4 
days 
A repeated measures ANOVA was conducted to determine if the concentration of SMX 
had an effect on the proliferation of control and DHS PBMCs. Mauchly’s test of 
sphericity was not significant (p = 0.681), therefore the assumption was met and a 
Greenhouse-Geisser correction was not used. F(4, 32) = 0.296, p = 0.878. N(control) = 4 
and N(DHR) = 4, ± SEM. 
4.3 Flow Cytometry Results 
4.3.1 Representative Flow Cytometry Charts 
To gate the PBMCs analyzed by flow cytometry, first live cells were gated according to 
viability dye (Figure 4-5-i). Then, single cells were gated until the cells could be gated as 
CD3+ and CD3- (Figure 4-5-v). CD3+ cells were further gated for being CD69+ (4-5-vi), 
CD4+ (4-5-vii), and CD8+ (4-5-viii). Both CD3+CD4+ and CD3+CD8+ T cells were gated 
for CD69 (4-5-x and 4-5-xi, respectively). In addition, CD3- cells were also examined for 
CD69 expression (Figure 4-5-ix). Just as CD69 expression can be represented as dot 
plots, it can also be presented as MFI of CD69 histograms (Figure 4-10). All gating and 
analyses were performed on FlowJo. All participants (both control and DHR) were gated 
in the same way.  
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Figure 4-5: Representative flow cytometry dot plot and gating procedure 
 
Figure 4-6: Representative MFI of CD69 expression histogram 
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4.3.2 Participants were Eliminated According to Cell Viability and 
Percent of CD3+ Cells 
The percent of live cells remaining after incubation with both SMX and AMX was 
assessed for each control and DHR participant. In addition to CD69 expression, cell 
viability and the percent of T cells (CD3+) of total cells acquired were looked at. Cell 
viability was measured using a viability stain that enters cells with compromised cellular 
membranes, and binds to proteins within the cell. Cells positively stained with the dye 
can be gated as dying or dead cells on the flow cytometer and can be excluded from 
subsequent analysis.  
Four DHR participants and three control participants were tested in culture media 
(unstimulated), four concentrations of SMX (100, 200, 400, 800 µM), and anti-CD3 (data 
not shown for anti-CD3). Within the DHR participants (DHS001-003, 008) tested (see 
Figure 4-7), two participants had cell viability under 50% across all conditions (DHS001, 
average cell viability of 38.12%, and 002, average cell viability of 9.18%). Two SMX 
concentrations could not be acquired in DHS008 (100µM and 200µM). Within the three 
control participants (Control001-003) tested (see Figure 4-8), Control002 had less than 
50% viability across all conditions (average cell viability of 14.43%). In Control001, only 
the SMX 800µM condition had viability at slightly under 50%, all other conditioners 
were higher. Because of these low viabilities, DHS001, DHS002, and Control002 were 
excluded from subsequent analyses. 
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Figure 4-7: Percent of live PBMCs analyzed from total number of DHR participant 
PBMCs after incubation with concentrations of SMX, acquired by flow cytometry, 
as a measure of cell viability	
PBMCs were incubated with culture media (unstimulated), anti-CD3, and SMX at 
concentrations 100µM, 200µM, 400µM, and 800µM.  
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Figure 4-8: Percent of live PBMCs analyzed from total number of control 
participant PBMCs after incubation with concentrations of SMX, acquired by flow 
cytometry, as a measure of cell viability	
PBMCs were incubated with culture media (unstimulated), anti-CD3, and SMX at 
concentrations 100µM, 200µM, 400µM, and 800µM. 
In addition to SMX, five DHR participants and four control participants were tested with 
culture media (unstimulated), four concentrations of AMX (10µM, 100µM, 500µM, 
1000µM), and anti-CD3. All participants, both DHR (see Figure 4-9) and control (see 
Figure 4-10), had cell viability greater than 50% (lowest viability was 70.77% and 
greatest was 90.39%), therefore all were included in subsequent analyses.  
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Figure 4-9: Percent of live PBMCs analyzed from total number of DHR participant 
PBMCs after incubation with AMX, acquired by flow cytometry, as a measure of 
cell viability 
PBMCs were incubated with culture media (unstimulated), anti-CD3, and AMX at 
concentrations 10µM, 100µM, 500µM, and 1000µM. 
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Figure 4-10: Percent of live PBMCs analyzed from total number of control 
participant PBMCs after incubation with AMX, acquired by flow cytometry, as a 
measure of cell viability 
PBMCs were incubated with culture media (unstimulated), anti-CD3, and AMX at 
concentrations 10µM, 100µM, 500µM, and 1000µM. 
The percent of CD3+ T cells was also analyzed by flow cytometry. Within the SMX DHR 
participants (see Figure 4-11), the percentages of CD3+ at each concentration were very 
different. DHS001 and DHS002 both had low percent of CD3+ T cells (averages of 
14.85% and 0.54%, respectively). In the SMX control participants (see Figure 4-12), 
Control002 also had a very low percentage of CD3+ T cells acquired (approximately 
1.31% across all conditions).  
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Figure 4-11: Percent of CD3+ cells analyzed from total number of DHR participant 
PBMCs after incubation with SMX, acquired by flow cytometry	
PBMCs were incubated with culture media (unstimulated), anti-CD3, and SMX at 
concentrations 100µM, 200µM, 400µM, and 800µM. 
 
Figure 4-12: Percent of CD3+ cells analyzed from total number of control 
participant PBMCs after incubation with SMX, acquired by flow cytometry	
PBMCs were incubated with culture media (unstimulated), anti-CD3, and SMX at 
concentrations 100µM, 200µM, 400µM, and 800µM. 
0
10
20
30
40
50
60
70
80
90
100
Unstimulated 100uM SMX 200uM SMX 400uM SMX 800uM SMX
%
 C
D
3 
ce
lls
 o
f t
ot
al
 a
cq
ui
re
d
DHS001 DHS002 DHS003 DHS008
0
10
20
30
40
50
60
70
80
90
100
Unstimulated 100uM SMX 200uM SMX 400uM SMX 800uM SMX
%
 C
D
3 
ce
lls
 o
f t
ot
al
 a
cq
ui
re
d
Control001 Control002 Control003
68 
 
As for AMX control (Figure 4-13) and DHR participants (Figure 4-14), most percentages 
of CD3+ T cells were high, except for DHS006, which was very low (average of 
approximately 0.74% across all conditions). Because of this, DHS006 was removed from 
all subsequent analyses.  
 
Figure 4-13: Percent of CD3+ cells analyzed from total number of DHR participant 
PBMCs after incubation with AMX, acquired by flow cytometry 
PBMCs were incubated with culture media (unstimulated), anti-CD3, and AMX at 
concentrations 10µM, 100µM, 500µM, and 1000µM. 
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Figure 4-14: Percent of CD3+ cells analyzed from total number of control 
participant PBMCs after incubation with AMX, acquired by flow cytometry 
PBMCs were incubated with culture media (unstimulated), anti-CD3, and AMX at 
concentrations 10µM, 100µM, 500µM, and 1000µM. 
4.3.3 Control and DHR Participant Results with SMX Incubation 
Two control and DHR participant results were analyzed after participants had been 
removed, and graphed according to percent of CD69 expression and MFI of CD69 across 
CD3+, CD3+CD4+, CD3+CD8+, and CD3- cell types as a result of incubation with 
increasing concentrations of SMX (Figures 4-15 to 4-30).  
With CD3+ cells (Figure 4-15 to 4-18), there was no increase in proliferation across 
concentrations, and no detectable difference between control and DHR participants. With 
percent CD69 (Figure 4-15), the only participant that had some increase beyond 
unstimulated was DHS008 at 800µM SMX. However, when averaged with DHS003 
(Figure 4-16), the average did not appear to be different from unstimulated. As for the 
individual MFI values (Figure 4-17), all values of control and DHR participant were at or 
below that of unstimulated regardless of concentration, which is also reflected in the 
averaged values (Figure 4-18).  
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It is important to note that as sample size of SMX participants is small, no statistics were 
calculated.  
With helper (CD3+CD4+) T cells, similarly to CD3+, there were no noticeable increases. 
With percent of CD69 expression (Figure 4-19 and 4-20), all normalized values were 
below normalized unstimulated levels. Only DHS008 had an increase between 400µM 
and 800µM SMX, however both values were not greater than unstimulated. MFI values 
were also lower than unstimulated for all concentrations (Figure 4-21 and 4-22). 
Control001 showed an odd increase compared to unstimulated in MFI with 100µM SMX, 
but was below unstimulated for all other concentrations (seen in Figure 4-21).  
As for CD3+CD8+, overall there were no noticeable differences between the 
concentrations of SMX. For percent CD69 (Figure 4-23), again DHS008 had a slight 
increase between 400uM and 800uM SMX, but not greater than unstimulated. 
Control001 had a slight increase over unstimulated for 100µM and 200µM SMX, but 
returned to at or below unstimulated in the higher concentrations. On average (Figure 4-
24), no concentrations showed an effect. With MFI (Figures 4-25 and 4-26), Control001, 
003 and DHS003 all had similar values, with none of the MFI values greater than 
unstimulated, however DHS008 MFI values at 400 and 800µM were very close to 0 
when normalized to unstimulated (Figure 4-25). On average, no overall differences were 
seen between the groups.  
Similar patterns were seen again with CD3- cell types (Figures 4-27 to 4-30). With 
percent CD69 (Figures 4-27 and 4-28), DHS008 showed again an increase between 
400µM and 800µM, which was slightly above unstimulated. Control001 showed an 
increase above normalized unstimulated for all concentrations, while Control003 and 
DHS003 values were all below normalized unstimulated. Overall, none of the average 
values differed from unstimulated (Figure 4-28). With MFI of CD69, Control001, 
Control003, DHS003 all were very similar to unstimulated values across all 
concentrations. Only DHS008 showed a low MFI at 400µM and 800µM concentrations. 
Overall the MFI of control values did not differ from unstimulated (Figure 4-29 and 4-
30), with DHS only slightly lower due to DHS008. 
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Figure 4-15: Percent of CD3+ T cells expressing CD69 in individual control and 
DHS participant PBMCs incubated with SMX 
 
Figure 4-16: Average percent of CD3+ T cells expressing CD69 normalized to 
unstimulated control, as a result of control and DHS participant PBMCs incubated 
with culture media (unstimulated control) and four concentrations of SMX 
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Figure 4-17: MFI of CD3+ T cells expressing CD69 in individual control and DHS 
participant PBMCs incubated with SMX 
 
Figure 4-18: Average MFI of CD69 on CD3+ T cells normalized to unstimulated 
control, as a result of control and DHS participant PBMCs incubated with culture 
media (unstimulated control) and four concentrations of SMX 
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Figure 4-19: Percent of CD3+CD4+ T cells expressing CD69 in individual control 
and DHS participant PBMCs incubated with SMX 
 
Figure 4-20: Average percent of CD3+CD4+ T cells expressing CD69 normalized to 
unstimulated control, as a result of control and DHS participant PBMCs incubated 
with culture media (unstimulated control) and four concentrations of SMX 
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Figure 4-21: MFI of CD3+CD4+ T cells expressing CD69 in individual control and 
DHS participant PBMCs incubated with SMX 
 
Figure 4-22: Average MFI of CD69 on CD3+CD4+ T cells normalized to 
unstimulated control, as a result of control and DHS participant PBMCs incubated 
with culture media (unstimulated control) and four concentrations of SMX 
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Figure 4-23: Percent of CD3+CD8+ T cells expressing CD69 in individual control 
and DHS participant PBMCs incubated with SMX 
 
Figure 4-24: Average percent of CD3+CD8+ T cells expressing CD69 normalized to 
unstimulated control, as a result of control and DHS participant PBMCs incubated 
with culture media (unstimulated control) and four concentrations of SMX 
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Figure 4-25: MFI of CD3+CD8+ T cells expressing CD69 in individual control and 
DHS participant PBMCs incubated with SMX 
 
Figure 4-26: Average MFI of CD69 on CD3+CD8+ T cells normalized to 
unstimulated control, as a result of control and DHS participant PBMCs incubated 
with culture media (unstimulated control) and four concentrations of SMX 
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Figure 4-27: Percent of CD3- PBMCs expressing CD69 in individual control and 
DHS participant PBMCs incubated with SMX	
 
Figure 4-28: Average percent of CD3- PBMCs expressing CD69 normalized to 
unstimulated control, as a result of control and DHS participant PBMCs incubated 
with culture media (unstimulated control) and four concentrations of SMX	
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Figure 4-29: MFI of CD3- PBMCs expressing CD69 in individual control and DHS 
participant PBMCs incubated with SMX	
 
Figure 4-30: Average MFI of CD69 on CD3- PBMCs normalized to unstimulated 
control, as a result of control and DHS participant PBMCs incubated with culture 
media (unstimulated control) and four concentrations of SMX	
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4.3.4 Control and DHR Participant Results with AMX Incubation 
A total of four control participants and four DHR participants for AMX were recruited 
for this study, which allowed statistical analyses to be performed, unlike with SMX.  
With CD3+ percent CD69 (Figure 4-31), Control004 was similar or lower to unstimulated 
across all concentrations, Control005 was highest at 10µM AMX but decreased to 
unstimulated levels at 1000µM. Control006 was similar to unstimulated but lowered a lot 
by 1000µM, and Control007 was lower than unstimulated through 500µM, but increased 
slightly past unstimulated at 1000µM. DHS004 was mostly similar to unstimulated 
except at 100µM AMX, and DHS005, while initially lower at than unstimulated at 10µM, 
increased above unstimulated values at 500µM and 1000µM. While DHS007 was 
consistent or lower than unstimulated, DHS008 had a spike at 10µM before returning 
around unstimulated levels. When comparing the average control and DHR participants 
across AMX concentrations (Figure 4-32), there were no significant differences observed. 
There was a slight but not significant increase in DHS averages at 10µM, 500µM, and 
1000µM AMX, and a slight decrease at 100µM, but none were significantly different 
from unstimulated when analyzed by repeated measures ANOVA. Control participant 
averages were very similar to unstimulated values. When a repeated measures ANOVA 
was conducted on the control averages alone, the p value was not significant (> 0.05).  
MFI for each individual participant (Figure 4-33) did not reveal any differences, other 
than DHS007 slightly increasing as concentration increased, and DHS008 was very low 
in comparison to the unstimulated values and the other participants (both control and 
DHS). With the average MFI values (Figure 4-34), other than a very slight but not 
significant increase at 500µM for the control participants, everything was very similar to 
unstimulated values and there were no significant differences between group or 
concentration. When analyzed by repeated measures ANOVA, neither control 
participants or DHS participant MFI levels showed no significant differences between 
treatment concentrations and unstimulated.  
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Figure 4-31: Percent of CD3+ T cells expressing CD69 in individual control and 
DHS participant PBMCs incubated with AMX 
 
Figure 4-32: Percent of CD3+ T cells expressing CD69 normalized to unstimulated 
control, as a result of PBMCs incubated with culture media (unstimulated control) 
and four concentrations of AMX 
A repeated measures ANOVA was conducted to determine if any concentration had a 
significant effect on CD69 expression by CD3+ T cells. Mauchly’s Test of Sphericity was 
insignificant (p = 0.277) and therefore the assumption of sphericity was met, and 
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therefore a Greenhouse-Geisser correction was not used. F(4,24) = 0.510, p = 0.729. 
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures 
ANOVAs were also conducted on CD3+ CD69+ control participants and DHS 
participants separately. For control participants, Mauchly’s Test of Sphericity was 
violated, therefore a Greenhouse-Geisser correction was used. F(1.281,3.842) = 0.043, p 
= 0.897. For DHS participants, Mauchly’s Test of Sphericity was violated, therefore a 
Greenhouse-Geisser correction was used. F(1.443,4.329) = 0.815, p = 0.461.  
 
Figure 4-33: MFI of CD3+ T cells expressing CD69 in individual control and DHS 
participant PBMCs incubated with AMX 
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Figure 4-34: MFI of CD3+ T cells expressing CD69 normalized to unstimulated 
control, as a result of PBMCs incubated with culture media (unstimulated control) 
and four concentrations of AMX 
A repeated measures ANOVA was conducted to determine if any concentration had a 
significant effect on CD69 expression by CD3+ T cells. Mauchly’s Test of Sphericity was 
insignificant (p = 0.491), the assumption of sphericity was met, and therefore a 
Greenhouse-Geisser correction was not used. F(4,24) = 0.155, p = 0.959. N(control 
participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures ANOVAs 
were also conducted on CD3+ CD69+ control participants and DHS participants 
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a 
Greenhouse-Geisser correction was used. F(1.531,4.593) = 1.232, p = 0.355. For DHS 
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser 
correction was used. F(1.916,5.748) = 0.073, p = 0.925.  
With CD3+CD4+, in the individual percent (Figure 4-35), most participants were very 
similar to unstimulated. With the control participants, Control005 increased above 
unstimulated at 10µM but decreased back down to unstimulated by 1000µM AMX. 
Control006 decreased at 1000µM, while Control007 increased at 1000µM. For the DHR 
participants, DHS004 increased at 10µM, decreased below unstimulated at 100µM, then 
returned to unstimulated values at 500 and 1000µM. DHS005 increased from below 
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unstimulated at 10µM and 100µM to increase above unstimulated at 500µM and 1000µM 
AMX. DHS007 was consistently lower than unstimulated across all concentrations, and 
DHS008 was close to unstimulated. When comparing average values at the different 
concentrations (Figure 4-36), there were no noticeable differences between the groups 
and unstimulated. A repeated measures ANOVA indicated no significant differences 
between any treatment groups and unstimulated for both control participants and DHS 
participants. Control006 was slightly increased at 100µM, and DHS008 was low across 
all concentrations similar to the other cell types. Individual MFI values did not reveal any 
obvious differences between participants (Figure 4-37). Comparing average MFI values 
(Figure 4-38) did not reveal any significant differences between control and unstimulated 
or differences between any of the AMX concentrations.  
 
Figure 4-35: Percent of CD3+CD4+ T cells expressing CD69 in individual control 
and DHS participant PBMCs incubated with AMX 
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Figure 4-36: Percent of CD3+CD4+ T cells expressing CD69 normalized to 
unstimulated control, as a result of PBMCs incubated with culture media 
(unstimulated control) and four concentrations of AMX 
A repeated measures ANOVA was conducted to determine if any concentration had a 
significant effect on CD69 expression by CD3+CD4+ T cells. Mauchly’s Test of 
Sphericity was insignificant (p = 0.471), the assumption of sphericity was met, and 
therefore a Greenhouse-Geisser correction was not used. F(4,24) = 0.555, p = 0.697. 
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures 
ANOVAs were also conducted on CD3+CD69+ control participants and DHS participants 
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a 
Greenhouse-Geisser correction was used. F(1.257,3.772) =0.043, p = 0.893. For DHS 
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser 
correction was used. F(1.508,4.524) = 1.354, p = 0.330. 
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Figure 4-37: MFI of CD3+CD4+ T cells expressing CD69 in individual control and 
DHS participant PBMCs incubated with AMX 
 
Figure 4-38: MFI of CD3+CD4+ T cells expressing CD69 normalized to 
unstimulated control, as a result of PBMCs incubated with culture media 
(unstimulated control) and four concentrations of AMX 
A repeated measures ANOVA was conducted to determine if any concentration had a 
significant effect on CD69 expression by CD3+CD4+ T cells. Mauchly’s Test of 
Sphericity was significant (p = 0.012), the assumption of sphericity was not met, and 
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therefore a Greenhouse-Geisser correction was used. F(1.832,10.995) = 1.685, p = 0.230. 
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures 
ANOVAs were also conducted on CD3+CD69+ control participants and DHS participants 
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a 
Greenhouse-Geisser correction was used. F(1.384,4.151) = 0.699, p = 0.496. For DHS 
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser 
correction was used. F(2.073,6.219) = 1.638, p = 0.269.  
CD3+CD8+ cell types did not show many individual differences with CD69 expression 
(Figure 4-39); only control004 showed a slight increase as with increasing concentrations 
with a slight decrease from 500µM to 1000µM, and DHS005 showed an increase as 
concentration increased. No other participants visibly differed from the control. With the 
average percent CD69 values (Figure 4-40), there were no significant differences found 
with the repeated measures ANOVA, either when the data for control and DHS 
participants was combined or when analyzed separately. There was a noticeable 
difference at 100µM AMX between control and DHS participants, where the control 
participant average was slightly higher, but this difference was not significant overall 
with the repeated measures ANOVA. Student’s t-test conducted between the control and 
DHS participants at 100uM had a p value of 0.069. With individual MFI values (Figure 
4-41), all values were similar to unstimulated. When the average MFI values were 
compared (Figure 4-42), no significant differences were observed with a repeated 
measures ANOVA. However, there is a difference seen at 1000µM, where the DHS 
participants mean MFI was slightly higher than control. While this difference was not 
significant with the ANOVA, a one-tailed student’s t-test revealed this comparison to 
have a p value of 0.0034.  
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Figure 4-39: Percent of CD3+CD8+ T cells expressing CD69 in individual control 
and DHS participant PBMCs incubated with AMX 
 
Figure 4-40: Percent of CD3+CD8+ T cells expressing CD69 normalized to 
unstimulated control, as a result of PBMCs incubated with culture media 
(unstimulated control) and four concentrations of AMX 
A repeated measures ANOVA was conducted to determine if any concentration had a 
significant effect on CD69 expression by CD3+CD8+ T cells. Mauchly’s Test of 
Sphericity was insignificant (p = 0.168), the assumption of sphericity was met, and 
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therefore a Greenhouse-Geisser correction was not used. F(4,24) = 0.714, p = 0.590. 
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures 
ANOVAs were also conducted on CD3+ CD69+ control participants and DHS 
participants separately. Repeated measures ANOVAs were also conducted on CD3+ 
CD69+ control participants and DHS participants separately. For control participants, 
Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser correction was used. 
F(2.026,6.079) = 0.019, p = 0.982. For DHS participants, Mauchly’s Test of Sphericity 
was violated, so a Greenhouse-Geisser correction was used. F (1.439,4.318) = 1.420, p = 
0.318. 
 
Figure 4-41: MFI of CD3+CD8+ T cells expressing CD69 in individual control and 
DHS participant PBMCs incubated with AMX 
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Figure 4-42: MFI of CD3+CD8+ T cells expressing CD69 normalized to 
unstimulated control, as a result of PBMCs incubated with culture media 
(unstimulated control) and four concentrations of AMX 
A repeated measures ANOVA was conducted to determine if any concentration had a 
significant effect on CD69 expression by CD3+CD8+ T cells. Mauchly’s Test of 
Sphericity was insignificant (p = 0.407), the assumption of sphericity was met, and 
therefore a Greenhouse-Geisser correction was not used. F(4,24) = 1.028, p = 0.412. 
N(control participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures 
ANOVAs were also conducted on CD3+ CD69+ control participants and DHS 
participants separately. For control participants, Mauchly’s Test of Sphericity was 
violated, so a Greenhouse-Geisser correction was used. F(1.669,5.007) = 3.677, p = 
0.107. For DHS participants, Mauchly’s Test of Sphericity was violated, so a 
Greenhouse-Geisser correction was used. F(1.979,5.936) = 1.672, p = 0.265.  
Similar patterns were seen with CD3- cells. With the individual participants (Figure 4-
43), most were very similar to unstimulated. Control004 was slightly lower across all 
concentrations than unstimulated, while Control007 decreased from unstimulated as 
concentration of AMX increased. DHS007 was consistently slightly higher than 
unstimulated at all concentrations. Overall, when the average values were compared 
(Figure 4-44), no significant differences were observed with a repeated measures 
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ANOVA. One small noticeable difference was seen again at 1000µM, where the DHR 
percent CD69 value was slightly higher than control. While not significant in the 
ANOVA, a student’s t-test at this concentration had a p value of 0.003. With individual 
MFI values, a few differences are seen (Figure 4-45). For the most part, values were 
consistent around unstimulated. DHS004 however increased from unstimulated as 
concentration increased, and there was a sharp increase in the MFI of CD69 with 
DHS005 at 100µM. DHS007 and DHS008 were consistently lower than unstimulated. 
With the average MFI values (Figure 4-46), there were no significant differences seen. 
The sharp increase of DHS008 is responsible for variability and an increase (but not 
significant) in average MFI values at 100µM.  
 
Figure 4-43: Percent of CD3- PBMCs expressing CD69 in individual control and 
DHS participant PBMCs incubated with AMX 
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Figure 4-44: Percent of CD3- PBMCs expressing CD69 normalized to unstimulated 
control, as a result of PBMCs incubated with culture media (unstimulated control) 
and four concentrations of AMX 
A repeated measures ANOVA was conducted to determine if any concentration had a 
significant effect on CD69 expression by CD3- T cells. Mauchly’s Test of Sphericity was 
insignificant (p = 0.437), the assumption of sphericity was met, and therefore a 
Greenhouse-Geisser correction was not used. F(4,24) = 0.719, p = 0.587. N(control 
participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures ANOVAs 
were also conducted on CD3+ CD69+ control participants and DHS participants 
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a 
Greenhouse-Geisser correction was used. F(2.233,6.700) = 2.833, p = 0.126. For DHS 
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser 
correction was used. F(1.449,4.348) = 1.050, p = 0.396.  
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Figure 4-45: MFI of CD3- PBMCs expressing CD69 in individual control and DHS 
participant PBMCs incubated with SMX 
 
Figure 4-46: MFI of CD3- PBMCs expressing CD69 normalized to unstimulated 
control, as a result of PBMCs incubated with culture media (unstimulated control) 
and four concentrations of AMX 
A repeated measures ANOVA was conducted to determine if any concentration had a 
significant effect on CD69 expression by CD3- T cells. Mauchly’s Test of Sphericity was 
significant (p = 0.022), the assumption of sphericity was not met, and therefore a 
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Greenhouse-Geisser correction was used. F(1.603,9.621) = 0.646, p = 0.513. N(control 
participants) = 4 and N(DHR participants) = 4, ± SEM. Repeated measures ANOVAs 
were also conducted on CD3+ CD69+ control participants and DHS participants 
separately. For control participants, Mauchly’s Test of Sphericity was violated, so a 
Greenhouse-Geisser correction was used. F(1.611,4.834) = 2.157, p = 0.212. For DHS 
participants, Mauchly’s Test of Sphericity was violated, so a Greenhouse-Geisser 
correction was used. F(1.481,4.443) = 0.477, p = 0.597.  
4.3.5 Comparison of SMX and AMX Grouped Concentrations 
Since four concentrations each of AMX and SMX were used, they were combined in 
increasing concentrations to see if there was any effect on increasing concentration on the 
isolated PBMCs from hypersensitive individuals. Control participants were not included 
in this analysis. Percent CD69 expression and MFI of CD69 values were normalized to 
unstimulated values. See Figures 4-47 to 4-54. 
Across all cell types, there were no significant differences in percent of CD69 expression 
or MFI of CD69 when drug concentration was increased. Overall, there did not seem to 
be any trends that exceeded unstimulated values. Within CD3+ cell types, the second 
concentration (C2) was consistently low in percent CD69 compared to unstimulated and 
other concentrations, but nothing was found by repeated measures ANOVA to be 
significant (Figure 4-47, 4-49, 4-51). There was a slight decrease from unstimulated in 
the MFI of CD69 on CD3+CD4+ cells (Figure 4-50). Within the CD3- cell types, the 
second concentration (C2) appeared to be very high, but also had high variability (Figure 
4-53).  
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Figure 4-47: Average percent of CD69 expression on CD3+ PBMCs isolated from 
hypersensitive participants, combining SMX and AMX concentrations 
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any 
differences among the unstimulated and the increasing drug concentrations of drugs. 
Mauchly’s Test of Sphericity was not violated. F(4,16) = 0.782, p = 0.553.  
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Figure 4-48: Average MFI of CD69 on CD3+ PBMCs isolated from hypersensitive 
participants, combining SMX and AMX concentrations 
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any 
differences among the unstimulated and the increasing drug concentrations of drugs. 
Mauchly’s Test of Sphericity was not violated. F(4,16) = 0.130, p = 0.969. 
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Figure 4-49: Average percent of CD69 expression on CD3+CD4+ PBMCs isolated 
from hypersensitive participants, combining SMX and AMX concentrations 
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any 
differences among the unstimulated and the increasing drug concentrations of drugs. 
Mauchly’s Test of Sphericity was not violated. F(4,16) = 1.468, p = 0.258.  
 
Figure 4-50: Average MFI of CD69 expression on CD3+CD4+ PBMCs isolated from 
hypersensitive participants, combining SMX and AMX concentrations 
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N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any 
differences among the unstimulated and the increasing drug concentrations of drugs. 
Mauchly’s Test of Sphericity was not violated. F(4.16) = 1.891, p = 0.161.  
 
Figure 4-51: Average percent of CD69 expression on CD3+CD8+ PBMCs isolated 
from hypersensitive participants, combining SMX and AMX concentrations 
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any 
differences among the unstimulated and the increasing drug concentrations of drugs. 
Mauchly’s Test of Sphericity was not violated. F(4,16) = 1.604, p = 0.222.  
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Figure 4-52: Average MFI of CD69 of CD69 expression on CD3+CD8+ PBMCs 
isolated from hypersensitive participants, combining SMX and AMX concentrations 
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any 
differences among the unstimulated and the increasing drug concentrations of drugs. 
Mauchly’s Test of Sphericity was not violated. F(4,16) = 0.758, p = 0.568.  
 
Figure 4-53: Average percent of CD69 expression on CD3- PBMCs isolated from 
hypersensitive participants, combining SMX and AMX concentrations 
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N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any 
differences among the unstimulated and the increasing drug concentrations of drugs. 
Mauchly’s Test of Sphericity was not violated. F(4,16) = 0.475, p = 0.753.  
 
Figure 4-54: Average MFI of CD69 expression on CD3- PBMCs isolated from 
hypersensitive participants, combining SMX and AMX concentrations 
N = 6, ± SEM. A repeated measures ANOVA was used to determine if there were any 
differences among the unstimulated and the increasing drug concentrations of drugs. 
Mauchly’s Test of Sphericity was violated (p = 0.41), therefore a Greenhouse-Geisser 
correction was used. F(1.480,5.921) = 0.559, p = 0.550.  
4.3.6 Control and DHS Participant Response to Anti-CD3 
In addition to analyzing the different concentrations of SMX and AMX compared to 
unstimulated, I also analyzed whether there were any differences between control and 
DHR participant response to anti-CD3 stimulation (Figures 4-55 to 4-62). To do this, all 
participants were combined, because anti-CD3 was the positive control for all 
participants regardless of drug type. Student’s t-tests were used to compare the percent 
CD69 expression and MFI of CD69 on CD3+, CD3+CD4+, CD3+CD8+, and CD3- cells.  
Overall, CD3- cells had a significantly lower percent expression of CD69 compared to the 
CD3+ cells. When activated with anti-CD3, all participant CD3+ cells had an average 
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percent CD69 expression of 33.10%, while CD3- had 1.27% (student’s t-test, one-tailed, 
p <0.005). This was similar for MFI of CD69 – CD3+ cells had an average MFI of CD69 
of 2.36, while CD3- had 1.27 (student’s t-test, one-tailed, paired, p < 0.01).  
The only instance where there was a significant difference between control and DHS 
participant response to stimulation with anti-CD3 was with the percent of CD3+ cells 
expressing CD69 (Figure 4-57). In this case, 27.68% of CD3+CD4+ cells were 
expressing CD69, which is significantly lower than the control participants, where 
65.42% of CD3+CD4+ cells were expressing CD69 (student’s t-test, one-tailed, p = 
0.043). Meanwhile, there were no significant differences in MFI of CD69 by CD3+CD4+ 
T cells in response to stimulation with anti-CD3 (student’s t-test, one-tailed, p = 0.38), 
see Figure 4-58. There were no other significant differences between any other responses 
to anti-CD3 in the other cell types analyzed (p > 0.05), see Figures 4-55 and 4-56, 4-58, 
4-59 and 4-60, 4-61 and 4-62.   
 
Figure 4-55: Average percent of CD69 expression on CD3+ PBMCs isolated from 
control and hypersensitive (DHS) participants stimulated with anti-CD3	
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3-
stimulated values. Student’s t-test, one-tailed, p = 0.39.  
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Figure 4-56: Average MFI of CD69 expression on CD3+ PBMCs isolated from 
control and hypersensitive (DHS) participants stimulated with anti-CD3	
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3-
stimulated values. Student’s t-test, one-tailed, p = 0.34.  
 
Figure 4-57: Average percent of CD69 expression on CD3+CD4+ PBMCs isolated 
from control and hypersensitive (DHS) participants stimulated with anti-CD3	
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N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3-
stimulated values. Student’s t-test, one-tailed, p = 0.049.  
 
Figure 4-58: Average MFI of CD69 expression on CD3+CD4+ PBMCs isolated from 
control and hypersensitive (DHS) participants stimulated with anti-CD3	
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3-
stimulated values. Student’s t-test, one-tailed, p = 0.22.  
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Figure 4-59: Average percent of CD69 expression on CD3+CD8+ PBMCs isolated 
from control and hypersensitive (DHS) participants stimulated with anti-CD3	
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3-
stimulated values. Student’s t-test, one-tailed, p = 0.20.  
 
Figure 4-60: Average MFI of CD69 expression on CD3+CD8+ PBMCs isolated from 
control and hypersensitive (DHS) participants stimulated with anti-CD3	
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3-
stimulated values. Student’s t-test, one-tailed, p = 0.19.  
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Figure 4-61: Average percent of CD69 expression on CD3- PBMCs isolated from 
control and hypersensitive (DHS) participants stimulated with anti-CD3	
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3-
stimulated values. Student’s t-test, one-tailed, p = 0.18.  
 
Figure 4-62: Average MFI of CD69 expression on CD3- PBMCs isolated from 
control and hypersensitive (DHS) participants stimulated with anti-CD3	
N = 6, ± SEM. Student’s t-test was used to compare control and DHS anti-CD3-
stimulated values. Student’s t-test, one-tailed, p = 0.12.  
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4.3.7 Combining SMX Concentrations in Control and DHS 
Participants 
In addition to comparing the effect of individual concentrations of SMX to unstimulated, 
the concentrations of SMX were combined by taking the average of percent CD69 
expression and MFI of CD69 and compared to unstimulated (Figures 4-63 to 4-70). 
Drug-stimulated values were normalized to unstimulated values. No significant 
differences were found between control and hypersensitive participants stimulated with 
SMX. However, in three instances, the drug-stimulated percent CD69 or MFI of CD69 
values were observed to be lower than unstimulated: CD3+CD4+ percent CD69 (Figure 4-
65), CD3+CD4+ MFI of CD69 (Figure 4-66), and CD3+CD8+ percent CD69 (Figure 4-
67). All others appeared to be similar to unstimulated.  
 
Figure 4-63: Average percent of CD69 expression of CD3+ PBMCs isolated from 
control and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of SMX 
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare percent of 
CD69 expression between control and DHS participants after exposure to SMX. 
Student’s t-test, p = 0.38.  
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Figure 4-64: Average MFI of CD69 expression of CD3+ PBMCs isolated from 
control and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of SMX 
N(control) = 2, N(DHS) = 2, ± SEM.  Student’s t-test was used to compare MFI of CD69 
expression between control and DHS participants after exposure to SMX. Student’s t-test, 
p = 0.49.  
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Figure 4-65: Average percent of CD69 expression of CD3+CD4+ PBMCs isolated 
from control and hypersensitive (DHS) participants as a result of exposure to 
combined concentrations of SMX 
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare percent of 
CD69 expression between control and DHS participants after exposure to SMX. 
Student’s t-test, p = 0.38.  
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Figure 4-66: Average MFI of CD69 expression of CD3+ PBMCs isolated from 
control and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of SMX 
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare MFI of CD69 
expression between control and DHS participants after exposure to SMX. Student’s t-test, 
p = 0.47.  
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Figure 4-67: Average percent of CD69 expression of CD3+CD8+ PBMCs isolated 
from control and hypersensitive (DHS) participants as a result of exposure to 
combined concentrations of SMX 
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare percent of 
CD69 expression between control and DHS participants after exposure to SMX. 
Student’s t-test, p = 0.42.  
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Figure 4-68: Average MFI of CD69 expression of CD3+CD8+ PBMCs isolated from 
control and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of SMX 
N(control) = 2, N(DHS) = 2, ± SEM.Student’s t-test was used to compare MFI of CD69 
expression between control and DHS participants after exposure to SMX. Student’s t-test, 
p = 0.26.  
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Figure 4-69: Average percent of CD69 expression of CD3- PBMCs isolated from 
control and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of SMX 
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare percent of 
CD69 expression between control and DHS participants after exposure to SMX. 
Student’s t-test, p =  0.43.  
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Figure 4-70: Average MFI of CD69 expression of CD3- PBMCs isolated from 
control and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of SMX 
N(control) = 2, N(DHS) = 2, ± SEM. Student’s t-test was used to compare MFI of CD69 
expression between control and DHS participants after exposure to SMX. Student’s t-test, 
p = 0.33.  
4.3.8 Combining AMX Concentrations in Control and DHS 
Participants 
All of the concentrations of AMX were combined to see if there was any effect between 
unstimulated and AMX in general. Student’s t-tests were performed between control 
AMX and DHS AMX values. No significant differences were found between these 
values with any cell type (Figures 4-71 to 4-78).  
All of the concentrations of AMX were combined to see if there was any effect between 
unstimulated and AMX in general. Student’s t-tests were performed between control 
AMX and DHS AMX values. No significant differences were found between these 
values with any cell type (Figures 4-71 to 4-78). Similar to SMX results, there were no 
significant differences found between control and hypersensitive participants stimulated 
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with AMX. There were no instances where AMX-stimulated values appeared lower than 
unstimulated.  
 
Figure 4-71: Average percent of CD69 expression of CD3+ PBMCs isolated from 
control and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of AMX 
N(control) = 4, N(DHS) = 4, ± SEM. Student’s t-test was used to compare percent of 
CD69 expression between control and DHS participants after exposure to AMX. 
Student’s t-test, p = 0.32.  
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Figure 4-72: Average MFI of CD69 of CD3+ PBMCs isolated from control and 
hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of AMX 
N(control) = 4, N(DHS) = 4; ± SEM. Student’s t-test was used to compare MFI of CD69 
expression between control and DHS participants after exposure to AMX. Student’s t-
test, p = 0.38.  
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Figure 4-73: Average percent of CD69 expression of CD3+CD4+ PBMCs isolated 
from control and hypersensitive (DHS) participants as a result of exposure to 
combined concentrations of AMX 
N(control) = 4, N(DHS) = 4, ± SEM. Student’s t-test was used to compare percent of 
CD69 expression between control and DHS participants after exposure to AMX. 
Student’s t-test, p = 0.28.  
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Figure 4-74: Average MFI of CD69 of CD3+CD4+ PBMCs isolated from control 
and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of AMX 
N(control) = 4, N(DHS) = 4; ± SEM. Student’s t-test was used to compare MFI of CD69 
expression between control and DHS participants after exposure to AMX. Student’s t-
test, p = 0.26.  
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Figure 4-75: Average percent of CD69 expression of CD3+CD8+ PBMCs isolated 
from control and hypersensitive (DHS) participants as a result of exposure to 
combined concentrations of AMX 
N(control) = 4, N(DHS) = 4, ± SEM. Student’s t-test was used to compare percent of 
CD69 expression between control and DHS participants after exposure to AMX. 
Student’s t-test, p = 0.35.  
0
20
40
60
80
100
120
140
160
Unstimulated AMX
Pe
rc
en
t 
CD
8+
 c
el
ls
 e
xp
re
ss
in
g 
CD
69
 
no
rm
al
iz
ed
 t
o 
un
st
im
ul
at
ed
Control DHS
118 
 
 
Figure 4-76: Average MFI of CD69 of CD3+CD8+ PBMCs isolated from control 
and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of AMX 
N(control) = 4, N(DHS) = 4; ± SEM. Student’s t-test was used to compare MFI of CD69 
expression between control and DHS participants after exposure to AMX. Student’s t-
test, p = 0.11.  
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Figure 4-77: Average percent of CD69 expression of CD3- PBMCs isolated from 
control and hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of AMX 
N(control) = 4, N(DHS) = 4, ± SEM. Student’s t-test was used to compare percent of 
CD69 expression between control and DHS participants after exposure to AMX. 
Student’s t-test, p = 0.14.  
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Figure 4-78: Average MFI of CD69 of CD3- PBMCs isolated from control and 
hypersensitive (DHS) participants as a result of exposure to combined 
concentrations of AMX 
N(control) = 4, N(DHS) = 4; ± SEM. Student’s t-test was used to compare MFI of CD69 
expression between control and DHS participants after exposure to AMX. Student’s t-
test, p = 0.38.  
4.4 Cytokine Analysis Results 
Cytokines IFN-y, IL-4, IL-9, IL-13, IL-17A, and IL-22 were analyzed by a custom 
Luminex kit by Bio-Rad. These cytokines were analyzed from the cell culture 
supernatant. Any cytokine secretion, if seen at all, occurred in anti-CD3 stimulated 
samples. Most results were highly variable due to only one sample of four having any 
detectable level of cytokine.  
IFN-7 was the only cytokine that had values in all conditions, however it is likely that 
most of these were extrapolations (specifically values under approximately 19 pg/ml). 
Anti-CD3 stimulation of both control and DHS PBMCs resulted in IFN-y secretion 
(Figure 4-79). Control004 had some secretion of IL-4, and IL-17A in the media (Figure 
4-80, 4-83). Anti-CD4 stimulation resulted in secretion of IL-4 and IL-9 in one DHS 
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participant only, and not in the controls (Figure 4-80, 4-81). IL-22 was also secreted 
when control and DHS participants were stimulated with anti-CD3 (Figure 4-84).  
It is important to note that if a bar is missing from the bar graph, it signifies that the result 
was 0, or that there were no detectable levels of cytokine. 
 
Figure 4-79: Observed concentration of IFN-y in pg/ml after incubation of PBMCs 
isolated from control and AMX-hypersensitive participants in anti-CD3, media 
(negative control), 100uM AMX, and 500uM AMX 
N(control) = 4, N(DHS) = 4.  
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Figure 4-80: Observed concentration of IL-4 in pg/ml after incubation of PBMCs 
isolated from control and AMX-hypersensitive participants in anti-CD3, media 
(negative control), 100uM AMX, and 500uM AMX 
N(control) = 4, N(DHS) = 4.  
 
Figure 4-81: Observed concentration of IL-9 in pg/ml after incubation of PBMCs 
isolated from control and AMX-hypersensitive participants in anti-CD3, media 
(negative control), 100uM AMX, and 500uM AMX 
N(control) = 4, N(DHS) = 4.  
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Figure 4-82: Observed concentration of IL-13 in pg/ml after incubation of PBMCs 
isolated from control and AMX-hypersensitive participants in anti-CD3, media 
(negative control), 100uM AMX, and 500uM AMX 
N(control) = 4, N(DHS) = 4.  
 
Figure 4-83: Observed concentration of IL-17A in pg/ml after incubation of PBMCs 
isolated from control and AMX-hypersensitive participants in anti-CD3, media 
(negative control), 100uM AMX, and 500uM AMX 
N(control) = 4, N(DHS) = 4.  
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Figure 4-84: Observed concentration of IL-22 in pg/ml after incubation of PBMCs 
isolated from control and AMX-hypersensitive participants in anti-CD3, media 
(negative control), 100uM AMX, and 500uM AMX 
N(control) = 4, N(DHS) = 4.  
The cytokine concentrations of IL-4, IL-9, IL-13, IL-17A, and IL-22 were secreted in 
much lower concentrations than IFN-γ in response in anti-CD3 stimulation (Figure 4-85). 
However, not all participants had cytokines secreted when stimulated with anti-CD3. All 
participants secreted some amount of IFN-γ upon stimulation (Figure 4-86). For example, 
DHS005 was the only participant secreting IL-4 (Figure 4-87) and IL-9 (Figure 4-88), no 
other participants secreted detectable amounts of these cytokines. DHS005 also secreted 
greater amounts of cytokines when secreted with anti-CD3 compared to the other 
participants. Most participants secreted some small amount of IL-13 and IL-17A (Figures 
4-89 and 4-90).  
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Figure 4-85: Average observed concentration of each cytokine analyzed in result to 
incubation of PBMCs isolated from control and AMX-hypersensitive participants 
with anti-CD3 
N(control) = 4, N(DHS) = 4.  
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Figure 4-86: Observed concentration of IFN-y (pg/ml) in response to incubation of 
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3 
N(control) = 4, N(DHS) = 4.  
 
Figure 4-87: Observed concentration of IL-4 (pg/ml) in response to incubation of 
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3 
N(control) = 4, N(DHS) = 4.  
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Figure 4-88: Observed concentration of IL-9 (pg/ml) in response to incubation of 
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3 
N(control) = 4, N(DHS) = 4.  
 
Figure 4-89: Observed concentration of IL-13 (pg/ml) in response to incubation of 
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3 
N(control) = 4, N(DHS) = 4.  
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Figure 4-90: Observed concentration of IL-17A (pg/ml) in response to incubation of 
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3 
N(control) = 4, N(DHS) = 4.  
 
Figure 4-91: Observed concentration of IL-22 (pg/ml) in response to incubation of 
PBMCs isolated from control and AMX-hypersensitive participants with anti-CD3 
N(control) = 4, N(DHS) = 4.  
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Chapter 5  
5 Discussion 
5.1 Aims and Objectives 
Adverse drug reactions account for approximately 5% of all hospital admissions and 
affect millions annually.5 Of these ADRs, DHRs account for approximately 20%.11,12 
Despite this, diagnosing DHRs is still difficult, resulting in overdiagnosis, reliance on 
substitute antibiotics, and limited understanding of the underlying mechanisms.3,18,27 
There are several competing hypotheses that attempt to explain how these DHRs occur 
(reviewed in § Pathophysiology of DHRs), however there is no consensus.  
The aim of this thesis is to study and characterize lymphocytes from peripheral blood 
samples from participants with clinical presentations suggestive of delayed-type drug 
hypersensitivity reactions by comparing them to healthy controls. Since the underlying 
cause and pathophysiology of T cell-mediated hypersensitivity reactions is still not fully 
understood, the goal was to use a combination of techniques to study drug-specific 
lymphocytes. Previous findings suggest that there are different T cells involved with 
different physical presentations of drug allergy. We hypothesized that differences in 
activated peripheral T cell subsets and types of mediators released have a direct impact 
on the clinical presentations of DHRs. We wanted to determine if there are any cell types 
or cytokines involved in the different clinical presentations we observed and recruited. 
We specifically chose sulfamethoxazole (SMX) and penicillin due to the high number of 
cases typically referred to Dr. Rieder’s clinic. Due to less than optimal cell count for the 
3H-thymidine and flow cytometry experiments, and RBC contamination in PBMCs 
leading to inconsistent cell counts in cytokine analysis, the results are inconclusive. 
However, this work has led to discovery of better methods and insights for 
improvements, optimization, and future studies.  
5.2 SMX Parent Drug was Best Form of Sulfamethoxazole 
Sulfamethoxazole, which inhibits the synthesis of tetrahydrofolic acid in bacteria,244 is 
metabolized in the liver by N-acetyltransferases and N-glucoronul-transferase, resulting 
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in the production of non-toxic metabolites.243 CYP-450 can also metabolize small 
amounts of SMX into two metabolites, SMX-NO and SMX-HA.247,248 Since SMX, SMX-
NO, and SMX-HA can be involved in the immune response,60,122,243 it was important to 
determine if any of these will cause damage to the PBMCs they would be incubated with. 
We know that SMX-HA is a reactive metabolite that can lead to greater cell death, so we 
needed to see if it would cause greater cell death than it would show cell activation. Our 
preliminary experiments used SMX and SMX-HA because SMX-NO was too unstable 
for use under the experiment conditions.  
First, I used PBMCs isolated from one volunteer and incubated these PBMCs with either 
unstimulated media, three concentrations of SMX, or three concentrations of SMX-HA. 
In the highest concentration of SMX-HA (100µM) used, there was a decrease in percent 
cell viability (Figure 3-1), but since sample size was only 1, I repeated the highest 
concentration with PBMCs isolated from two additional volunteers and found a 
significant decrease in percent cell viability after incubation (Figure 3-2). Therefore, we 
chose SMX since it did not negatively affect cell viability like SMX-HA. 
5.3 54 Hour Incubation was the Optimal Length of Time 
We needed to determine what the optimal length of time for incubating PBMCs with 
universal mitogen to minimize cell death and to show maximum activation. Since we 
used CD69 as an activation marker, this would show how CD69 is expressed over a time 
course and allow us to decide how long to incubate the PBMCs with drugs for. If the 
incubation time is not optimal, we would not see the maximum number of CD69-
activated cells, and it would be more difficult to see an effect since dividing cells would 
closely resemble non-dividing cells. This experiment was modeled after a similar 
experiment by Beeler et al.,295 however we added an extra timepoint and used control 
participants only.  
I isolated PBMCs from three volunteers. After incubating the isolated PBMCs for 
intervals of 18 hours for a total of 90 hrs with anti-CD3, and staining for viability and 
CD69, we found a decrease in live cells (Figure 3-3). A rANOVA revealed that there was 
a significant decrease in cell viability as incubation time increased.  
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For determining the optimum length of incubation time for best CD69 expression, no 
significant timepoints were found for any of the cell types (CD3+, CD3+CD4+, 
CD3+CD8+) examined (Figures 3-4 to 3-9). There was considerable variability across all 
timepoints, specifically in the MFI values. There were some noticeable but not significant 
increases at 54 hours for CD3+ and CD8+ cells (Figures 3-3, 3-5), while CD4+ cells had 
the highest CD69 expression at the 18-hour timepoint.  
Overall an incubation time of approximately 54 hours was chosen as a compromise 
between cell viability and CD69 expression. If closer to 90 hours was chosen, that would 
have left only approximately 50% of cells in the sample viable, even if there is no 
significant difference between 54 hours and 90 hours for percent CD69 expression.  
For this experiment, both anti-CD3-stimulated and unstimulated samples were prepared 
for flow cytometry analysis, and the unstimulated values were subtracted from the 
stimulated values. However, it would be wise to repeat this experiment with a 0-hour 
timepoint to better normalize the timepoints in addition to stimulated and unstimulated 
samples at each timepoint.  
5.4 Participant Recruitment 
For this study, patients were recruited from Dr. Michael Rieder’s drug safety clinic at 
London Health Sciences Centre, Victoria Hospital in London, Ontario. This research 
would not be possible without this direct access to ADR patients.  
While we are fortunate to have potential access to a wide number of people of all ages 
seeking an in vitro toxicity assay for potential ADRs, there are some pitfalls. Typically, 
these participants are referred to the clinic by their primary care physician due to a 
suspected previous ADR to a drug their primary care physician is interested in 
prescribing them. However, many times these participants have no real recollection of 
when the reaction occurred, let alone the specifics including type of resulting skin 
reaction or how many days after ingestion of the drug that the reaction occurred. This is 
the primary reason why some cases are described as “rash, unspecified.”  These patients 
are included due to a positive LTA. The LTA test typically occurred sometime in the 
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previous 10 years before this study. It has been previously reported that drug-specific T 
cells can be re-activated after 12 years since previous exposure122 or over 20 years since 
previous exposure.301 Recruitment was challenging, as the participants often would not 
answer phone calls, phone number was out of service and not updated with hospital, no 
interest, no availability, or difficulty accessing RRI due to location of home or work.  
We opted to test adult former patients (>18 years of age at the time of study) due to more 
easily obtained consent and a larger volume of blood drawn. Children and adolescents 
would be more complicated due to parental consent, for example parents might not be 
inclined to have blood drawn from their children for research. Children would also have 
to be taken out of school, or their parents would have to drive them before or after, while 
adults are usually more flexible with schedules and transportation.  
Out of all of Dr. Rieder’s former patients, many were eliminated immediately if the result 
of their LTA was negative. From all of the patients with positive LTAs, we excluded all 
those not positive to sulfamethoxazole and penicillin. I verified the final selected 
patients’ LTA results, confirmed their eligibility to participate with Dr. Rieder, called 
former patients for consent to participate, and explained the contents of the letter of 
information and consent package over the phone (see Appendix §	Letter	of	Information).			
In addition, participants were also recruited directly from Dr. Rieder’s clinic at the same 
time as LTA testing. These participants were asked to participate either because they had 
a strong history indicative of a delayed type ADR to either sulfamethoxazole or 
penicillin, or because they already had testing and were doing a re-test for a different 
drug.  
The participant pool consisted of middle-aged women with the exception of one man.  
Many of the participants eligible to participate were women; I did call prospective male 
participants, however many did not return my phone call. In contrast, the women I spoke 
to seemed very eager to participate in the study. It is also worth noting that while my 
study is biased towards women, ADRs are also more prevalent in women. There are a 
few possible explanations to why more women were recruited. The first being that more 
women tend to access health care services and have more consultations with their GP 
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than men do, and in effect are prescribed more antibiotics. The second reason is women 
are more often diagnosed with an ADR than men. Overall, women are prescribed more 
antibiotics than men,32 especially for conditions such as RTIs,32,33 and UTIs.32 Women 
also seek primary care much more than men do.34,302,303 Women also have physiological 
differences, such as higher levels of CYP450, different levels of hormones, different rates 
of drug conjugation, and differences in body mass.35–38  
Recruitment of participants also depends on the location of the patient themselves. The 
clinic often acquires samples from referred patients who live outside of London, often 
around Toronto or elsewhere throughout Southwestern Ontario. Many of these patients 
have a positive LTA and a history of ADR to the drugs that we are interested in, however 
often it is not possible to acquire a sample due to the participant residing outside of 
London. This can be due to a variety of reasons, some of which were experienced over 
the course of the recruitment of patients. Often, private clinics (ie. Life Labs or 
community health services) are inconsistent with their ability to draw blood for this 
lab/clinic. In addition, patients are often not motivated enough to participate, since it 
often involves driving to University Hospital or Robarts, which is inconvenient for many 
in addition to not wanting an extra blood test. Many of the patients were able to 
participate in this study by simply happening to be in the area at the time. 
It would open up many more opportunities for patient recruitment if we could access 
these samples outside of the London area, or arrange with other clinics around London to 
be able to draw the blood to make it easier for participants who work during the day. 
Currently, University Hospital can do draws from about 8 am until 4 pm daily, but other 
private clinics might be open on the weekends or in the evenings. In the future it would 
be ideal to make arrangements with other hospitals or blood-drawing clinics in other 
cities to access a greater number of participants.  
5.5 Defense of Drug Choice 
Sulfamethoxazole and penicillin were chosen as our culprit drugs of choice, rather than a 
survey of all drugs tested for in the clinic, because these two drugs are some of the most 
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commonly tested for. We were able to obtain a large list of potentially eligible 
participants, some of which had consented to be a part of Dr. Rieder’s database.  
However, there are some of the downsides of these drug choices, one example being 
sulfamethoxazole. SMX is a frequently prescribed antibiotic for UTIs,304 which are 
mostly seen in women. While they can and do occur in men, typically men do not suffer 
from as many UTIs due to increased length of urethra,305–307 among other reasons 
including urethral opening proximity to vaginal mucosa compared to the dry epithelium 
of the glans penis.305,306  
Choosing the appropriate reactive metabolite was important (see section Determining 
Best Form of Sulfamethoxazole). As previously mentioned, SMX-NO, and SMX-HA are 
reactive metabolites of SMX. SMX-NO has previously been used in studies.243 SMX-HA 
is used in Dr. Rider’s LTA analyses. Currently in the lab, we have stock of SMX-HA and 
SMX, however SMX-NO is unstable, so it would not be as useful. We found SMX-HA to 
negatively affect cell viability (Figures 3-1 and 3-2). In addition, it would be interesting 
to use liver microsomal metabolites rather than the AMX parent drug, to allow for 
reactive metabolites to be used in the experiment.102,257  
5.6 Scintillation Counting 
Beeler et al. suggest that a SI of at least 2 is a moderately positive result for DHR when 
using the LTT, while a SI of 3 is a strong positive result.295  
Scintillation counting was performed on both SMX and AMX groups of participants, 
after incubation of 54 hrs (established as incubation length for flow cytometry) and 4 
days. I found none of the concentrations of SMX or AMX caused a significant increase in 
SI at either timepoint (Figure 4-1, 4-3, Figure 4-5, 4-7). In addition, the age of the 
participant did not correlate with any noticeable increase in SI.  
In some of the raw data for the scintillation counting, the cpm were low for anti-CD3-
stimulated PBMCs and some for drug-stimulated samples were indistinguishable from 
unstimulated wells. I learned later on that there was an issue with cell counting and there 
was increased RBC contamination after the experiment was complete. I did not know I 
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was making this error and it was not corrected in time. We had previously attempted this 
when testing different mitogens and T cell stimulants (ex. anti-CD3, PHA, etc) and the 
results were better. In order to improve on this and obtain the results shown in other 
successful LTT studies, the incubation time should be extended to six days and the cell 
counting optimized to decrease RBC contamination.  
Another possibility in the future would be to use CFSE (carboxy fluorescein succinimidyl 
ester) instead of 3H-thymidine incorporation. CFSE is a common flow cytometry-based 
assay to assess cell proliferation, and it works by staining desired cells with CFSE before 
incubation, and quantifying the labelled cells by number of divisions. There is a 
progressive halving of fluorescence with each cell division.308 There are several benefits 
to using CFSE over 3H-thymidine incorporation. First, there is no radiation required and 
therefore no radiation permits or special training would be required. In addition, since it’s 
a flow cytometry-based assay, it can discriminate between cell types, for example 
between CD4+ vs CD8+ cell types dividing, if those surface markers are also stained 
for.308 CFSE is also stably and uniformly incorporated into cells, meaning cells can be 
cultured for weeks and still have measurable levels of CFSE remain in the cells.309–313 
Previous studies have used CFSE to stain T cells for cell proliferation in response to drug 
stimulation after six-122,295,314 or seven-315 day incubations. 
One potential downside of this method would be cost – the flow cytometer is rented with 
a set rate. One bottle of 3H-thymidine can last a long time, one well only requires 1ul, and 
use of the scintillation counter is free to the lab. For the CFSE analysis by flow 
cytometry, a new experiment would have to be set up with CFSE, in addition to all other 
desired fluors (for example, to differentiate T cells from PBMCs, and different T cell 
subsets), with our own FMO and isotype controls. A separate flow cytometry 
appointment would need to be set up aside from CD69 experiments, since staining for 
CD69 is done after only 54 hours of incubation, instead of six days. 
5.7 Flow Cytometry 
Flow cytometry was used with the stimulated PBMCs to determine which type of cell 
(CD3+, CD3+CD4+, CD3+CD8+, CD3-) was expressing CD69. These PBMCs were gated 
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according to cell surface marker expression as dot plots (Figure 4-5) and as histograms 
(Figure 4-6).  
First, flow cytometry results were used to screen participants. Both cell viability and 
percent CD3 cells of total cells acquired were examined. To include participants, it was 
decided that the majority of PBMCs analyzed had to be alive (>50% cell viability after 
staining with fixable viability dye). With SMX participants (consisting of four DHR 
participants and three control participants), two DHS participants had viability less than 
50% (Figure 4-7), and one control participant (Figure 4-8). It is not clear why these 
particular participants (DHS001, DHS002, and Control002) had low cell viability. For 
AMX testing, there were five DHR participants and four control participants. All 
participants had cell viability greater than 50% (Figures 4-9 and 4-10) so no AMX 
participants were excluded on this basis.  
In addition to cell viability criteria, participants were also excluded based on percent of 
CD3+ T cells acquired. If this percentage was too low, there would not be enough to see 
cells in gates further in the flow cytometry analysis. Typically, CD3+ T cells are 
approximately 70% of the composition of PBMCs.78–82,316,317 However, since there is 
individual variation between individuals, we removed participants with less than 30% of 
CD3+ cells acquired. Because of this, for SMX participants, DHS001, DHS002, and 
Control002 were removed – these were previously removed due to low cell viability. Out 
of the AMX participants, DHS006 was removed for a very low percentage of CD3+ T 
cells. This is likely because once the blood was drawn, the laboratory that drew the blood 
refrigerated the sample, causing red blood cell contamination in the PBMC layer during 
Ficoll separation. This tube was centrifuged for longer to attempt to remove more RBCs, 
however the RBC count was still very high which was especially noticeable in the flow 
cytometry results.  
For SMX participants, there was no significant increase in percent CD69 or MFI of CD69 
across any of the cell types (CD3+, CD3+CD4+, CD3+CD8+, CD3-, see Figures 4-15 to 4-
18, 4-19 to 4-22, 4-23 to 4-26, 4-27 to 4-30, respectfully). There was some variability in 
the groups at each concentration, however there were not enough participants to draw 
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conclusions. At the 100µM and 200µM SMX concentrations for DHS participants, one of 
the participants had very low cell numbers at these concentrations so these samples had to 
be removed. 
There were few participants (N < 3 in each control and DHS) in this portion of the study, 
therefore no statistics could be performed. Ideally more participants would be recruited 
with hypersensitivities to SMX. To improve collection and results, red blood cell 
contamination would be reduced at the counting stage, and more cells would be acquired 
by flow cytometry (upwards of 50 000 cells).  
Similar to SMX results, there was no significant increase in percent CD69 or MFI of 
CD69 across any of the cell types (CD3+, CD3+CD4+, CD3+CD8+, CD3-), see Figures 4-
31 to 4-34, 4-35 to 4-38, 4-39 to 4-42, 4-43 to 4-46. There were some noticeable 
increases in a few instances in each cell type, however none of these increases were 
significant. There were two instances in this analysis where there was a noticeable 
difference between control and DHS. At 100µM AMX, the percent of CD69 on control 
CD3+CD4+ cells was higher than the DHS cells. This is unexplained and could be 
attributed to several things, including too few participants and low cell count. In addition, 
with CD3- cells, there was greater CD69 expression on DHS cells compared to control 
cells at 1000µM. There were no other noticeable differences at the other concentrations. 
While this difference could also be attributed to error, this concentration is also high and 
could have had an effect on CD69 expression. Again, there should be a greater number of 
participants, more cells acquired, and use of an isotype control to confirm this.  
In addition to looking at each concentration individually, the increasing concentrations 
were grouped as concentration 1 (C1, 10µM AMX and 100µM SMX), concentration 2 
(C2, 100µM AMX and 200µM SMX), etc (Figures 4-47 to 4-54). This analysis was done 
with results from the DHS participant group across both SMX and AMX participants. 
The goal was to see if there are any noticeable increases across increasing concentrations. 
These were separated according to cell type, percent CD69 expression and MFI of CD69, 
similar to previous analyses. Similar to other results, there were no significant differences 
between unstimulated and increasing concentrations across any cell types.  
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There were only a few noticeable, but not significant, differences. First with CD3+CD4+ 
percent CD69, at C2 (200µM SMX, 100µM AMX) there was an observable decrease 
below unstimulated and the other concentrations, while the other concentrations (1, 3, 4) 
showed no difference from unstimulated. CD3+CD4+ MFI of CD69 had a slight decrease 
across concentrations, however none of these concentrations differed from unstimulated. 
With CD3- MFI of CD69, C2 had large variability, which was different from the other 
concentrations, which did not differ from unstimulated. It is not fully known why these 
small differences occurred, however as with the previous analyses, a larger participant 
group, improved methods, the results would be more accurate.  
Another analysis that was done was to look at how the control and DHS participants 
responded to anti-CD3 stimulation (Figures 4-55 to 4-62). Since anti-CD3 is a positive 
control for all of the participants across both drug types, all participants were combined 
regardless of which drug they had a hypersensitivity to. First, CD3- had a lower percent 
CD69 compared to CD3+ cells, which is still consistent considering while some cells in 
the CD3- population might express CD69, they may not express this protein in the same 
capacity as T cells, or some may not express it at all.  
There was one instance in this analysis where there was a difference between the percent 
of CD69 being expressed between control and DHS cells. CD3+CD4+ control PBMCs 
expressed a significantly higher percent of CD69 when compared to DHS participants 
when stimulated with anti-CD3 (Figure 4-57), however this difference was not reflected 
in the MFI of CD69 (Figure 4-58). This means that more cells expressed similar numbers 
of CD69. The reason for this is unknown so far. 
AMX concentrations were combined to see if control or DHS participant PBMCs reacted 
differently to incubation to amoxicillin in general, regardless of concentration (Figures 4-
71, 4-72 to 4-77, 4-78). There were no significant differences between control and DHS 
participants in either percent of CD69 or MFI of CD69 across all cell types. While this 
analysis does not take into account how the PBMCs would respond in different 
concentrations, it is reasonable to expect some differences across the concentrations that 
would affect CD69 expression.  
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Beeler et al. (2008) demonstrated that 1.9% of CD4+ T cells from drug-allergic 
participants expressed CD69 in response to sulfapyridine, 1.1% in response to tetanus 
toxoid, and 0.1% to media. In our flow cytometry analysis, we did not see this. However, 
when looking at very few PBMCs, our analysis could be only seeing a few stimulated T 
cells. Increasing the number of PBMCs analyzed would increase the number of 
CD4+CD69+ T cells, which would make the difference between CD69- and CD69+ cells 
more distinct. Deciding on where to place the gate for the CD69- T cells was decided by 
FMOs, however isotype controls should be used to place the gate more accurately. This is 
because isotype controls reduce non-specific binding of fluorescent-labeled antibodies. 
Even if we are seeing this 1-2% activation in T cells, it could be lost in the murky area 
between CD69+ and CD69- due to lack of isotype controls.  
With flow cytometry, starting cell count does not matter as much as cells are counted 
during analysis, and analysis is stopped once a certain threshold is reached. In the future, 
a greater number of cells should be analyzed, instead of 10000, closer to 100 000 
PBMCs. This, coupled with decreasing RBC contamination, could show more CD69+ 
cells if they exist in the sample, making a positive response more noticeable.   
There are also some improvements that can be made to the protocol, which can be 
established with improvements in the number of fluorescent channels on a flow 
cytometer, or the availability of such a flow cytometer at Western University. The 
fluorescent antibodies that were used for this experiment included CD3-APC, CD4-PE, 
CD8-BV421, and CD69-PE-Cy7. CD3 is a pan-T cell marker, CD4 is present on Th cells, 
CD8 is present on CTLs, and CD69 is a T cell activation marker.105,225,229,318 These four 
markers are for broad classes of T cells and activation, and we could get more specific 
than this. In the future, we could look at activation of more specific types of Th cells, 
including Th1, Th2, Th9, Th17, Th22, and Treg cells by flow cytometry by introducing 
other markers to the flow panel.  
This study is very underpowered. For the flow cytometry work alone, if looking at drug 
and control, we would need N=28, or N=14 each for patient participants and controls, for 
each drug, for 80% power. This power calculation was performed by using the 
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differences in percent of CD69 T cells in response to drug stimulation observed in the 
study conducted by Beeler et al.295 Adding in different clinical presentations would 
increase the number of participants. With six conditions, drugs, and participant/control 
groups, the required participant number increases to 72, with N = 12 per condition. The 
work completed so far has only 8 participants in total and is therefore incredibly 
underpowered. In addition to making adjustments to the methods, many more participants 
would need to be recruited. One benefit though is that this experiment could be 
considered a pilot project, to further provide insight into future studies.  
5.8 Luminex 
A custom Luminex assay purchased from Bio-Rad was used to assess the concentrations 
of IFN-y, IL-4, IL-9, IL-13, IL-17A, and IL-22 in the cell culture supernatant. Four DHS 
participants and their corresponding controls were selected from the AMX participants. 
DHS006 and Control006 were not chosen due to high RBC contamination and low 
percentage of CD3+ cells observed in flow cytometry results. 
The majority of the samples that expressed any level of cytokine were those stimulated 
with anti-CD3. Anti-CD3 promotes cell proliferation which could lead to greater amounts 
of cytokines released. Few cells in tested cultures would produce undetectable amounts in 
control and drug treatments. However, these results were highly variable because usually 
only one or two participants of the four had a measurable release of cytokines. None of 
the samples incubated with 100µM and 500µM AMX secreted detectable levels of 
cytokines, and most of the control (media) did not secrete any detectable levels of any of 
the cytokines. Only DHS005 secreted low but detectable levels across all six cytokines 
evaluated.  
Given that there are likely inconsistent numbers of cells across samples, a protein 
quantification would be required to compare samples to each other. The total protein 
acquired would be divided by the amount of cytokine secretion to normalize to protein 
content. However, only the supernatant was used and it was frozen to accumulate enough 
samples for Luminex. The cells were centrifuged and the supernatant was collected off 
the top, and the plate and cells were discarded. In addition, the media used was 
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supplemented with 10% human serum, which contains protein. Our original concept was 
to conduct a total protein quantification on the remaining supernatant used for Luminex, 
and use RPMI 1640 + 10% human AB serum as background. This background protein 
quantification would be subtracted from the protein content of the samples. We attempted 
to do this and tested the controls and standard curve with the protein quantification kit. It 
was recommended to use a buffer without protein, such as 1% PBS. After analyzing the 
standard curve prepared in both PBS and RPMI 1640 + 10% human AB serum, the media 
curve was very warped, and it was suggested by BioRad that the media and serum were 
not compatible with the kit. It is also a possibility that the proteins in the kit increased the 
total protein content higher than the upper limit of the kit. In the future, it would be 
beneficial to ensure the PBMC concentration is the same among all participants with 
more accurate cell counting. In addition, conduct protein quantification alongside 
isolating and freezing the supernatant, so that cells could be lysed and a total protein 
quantification could be done on lysed cells. Alternatively it could be done as it was, and 
the supernatant could be frozen and analyzed later. It would also be beneficial to leave 
out the serum if we will be doing a protein quantification.  
Other methods we had previously considered included ELISAs (enzyme-linked 
immunosorbent assay) and ELISpot (enzyme-linked immunospot) assays. An ELISpot is 
similar to an ELISA, however the cells are bound to the bottom of a 96-well plate, and 
the cytokines being released are also bound to the bottom of the plate, near the secreting 
cell. When the dye is applied, the cell secreting the cytokine being analyzed turns blue. 
The number of cells secreting the cytokine can be counted. This method would be useful 
if we tried cloning drug-specific T cells.104 ELISAs could be used, however each kit for a 
single cytokine was approximately $600. For this initial attempt, Luminex was less 
expensive. However, if this experiment continues in the future, the ELISAs may be a 
more economical solution. In addition, the ELISA kit has the ability to measure 
additional proteins, including granzyme B, which is secreted by cytotoxic T cells. 
Granzyme B, for example, is not measurable by the Bio-Rad customizable Luminex kit 
we used. This would be relevant due to the involvement of cytotoxic T cells in Stevens-
Johnson Syndrome, for example Chung and Hung 2010, Murata et al. 2008, among 
others.270,272 
142 
 
In addition to surface phenotyping greater populations of T cells by flow cytometry, we 
can also look at cytokine secretion using flow cytometry. While Luminex is a viable 
solution, it could be beneficial to try intracellular cytokine staining. One downside to this 
is that the flow cytometer currently available is able to examine 14 colours. We would 
have to carefully choose which cytokines to analyze in order to accommodate the 
viability dye, cell surface markers, and intracellular dyes. However, to accomplish all of 
this at once by flow cytometry, the staining would take more time and the flow cytometer 
would require more fluorescent channels, depending on how many Th cell types are being 
analyzed and how many cytokines would be looked at.  
To correctly power this study for Luminex, a survey of the literature for the difference 
between baseline and stimulated cytokine concentrations for each cytokine would need to 
be done. A smaller difference would require additional participants to support a 
conclusion.  
5.9 Future Studies 
There are many future directions that can be taken with this project. Regarding 
participant recruitment, it would be prudent to focus more on recruiting more age- and 
sex-matched controls. In this current study, the gender profiles of the DHR participants 
differed from those of the controls, as well as the average age was significantly older in 
the DHR compared to the controls. Another interesting avenue to explore would be 
matching the reason the drug was taken. For example, if one participant had a DHR to 
SMX taken for a UTI, then the control would have taken SMX for a UTI but did not have 
a reaction.  
An interesting direction this research could take is to genotype HLA-type participants in 
addition to the in vitro testing done. There are many GWAS (Genome-Wide Association 
Studies) from throughout the globe,319–323 including some in Canada.324 It would be 
beneficial to genotype adult patients recruited, and also extend this to paediatric patients 
as well. These GWAS help to identify culprit genes that contribute to the development of 
ADRs, and are often specific to origin/ethnicity. Genotyping is a huge component of 
personalized medicine. By phenotyping people who have or have had ADRs, we can look 
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for patterns between genes (specifically HLA genes), drug type and clinical presentation. 
This would be extremely beneficial to people who are looking to take a specific drug. 
With so few participants, this is a low-powered study, especially considering the vast 
numbers of different skin reactions that exist and recruiting more people over time to 
increase the number of hypersensitive participants as well as controls to increase the 
power would reveal more promising results.  
Children are some of the most common users of prescription antimicrobials.325 It would 
be very beneficial to include children into this analysis. Children are not just smaller 
versions of adults: the physiology of a child and their ability to metabolize drugs is 
different than that of an adult, in addition to several other differences.326,327 While there 
could be a genetic component to penicillin hypersensitivity in children, it could be 
another underlying pathway resulting in adverse reactions occurring.328 One of the main 
reasons children were excluded from this study is because of the volume of blood 
required for the study. With adults, we drew approximately 15 ml of peripheral blood, 
while in children typically we must draw less because they are smaller. Improving the 
methods, for example by combining the current methods into one large flow cytometry 
panel, could decrease the total number of isolated PBMCs required to acquire the same 
information. This would decrease the amount of blood required to be drawn, which could 
open up this experiment to consenting and assenting children and teenagers.  
In addition to collecting and plating PBMCs for Luminex, I originally isolated CD3+ cells 
for plating for cytokine release. However due to the cost of reagents for one 96-well plate 
and prioritizing PBMCs over isolated T cells, the supernatant for these T cells is still 
frozen. This is important since there would be no RBC contamination unlike in the 
PBMC experiments. The cell count is consistent across all samples and these samples 
could be tested reliably without protein quantification. While limited by not including 
CD3- derived cytokines, it would be interesting to see T cell only derived cytokines 
profiles. Ideally this analysis would be run alongside PBMCs.  
Our current study asked participants who had a DHR diagnosed in previous years, similar 
to previous reports (for example Beeler et al. 2007).295 It would be interesting to continue 
144 
 
this research in DHR patients who are currently undergoing a DHR, and also get leftover 
skin biopsy and blister fluid samples from active lesions. Some previous studies have 
done this, and have examined activated T cells and cytokines present in both peripheral 
blood and skin/blister fluid with promising results.275 They also analyzed peripheral 
blood during an active DHR and after resolution. This is important since it can 
demonstrate important diagnostic markers.  
5.10 Conclusions 
Overall, we cannot draw conclusions due to too few subjects and the need for different 
experimental approaches. However, there are several improvements that can be made that 
have been proposed. In the future it would be prudent to adjust the methods, including 
using flow cytometry to measure proliferation instead of scintillation counting. We could 
also expand the number of T cell subsets we analyze, by both increasing the surface 
markers by flow cytometry and the cytokines tested using a bead-based detection assay. It 
would be interesting to look at different drugs in addition to sulfamethoxazole and beta 
lactam antibiotics, to learn more about the role drug type has with DHRs. This study 
could span years to accumulate enough participants and increase power. There is much 
work to be done in the field of drug hypersensitivity; efforts put towards faster 
identification and detection of DHRs can contribute to decreased healthcare burden and 
increased quality of life.  
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Appendices 
List of Abbreviations 
ADR – adverse drug reaction 
AGEP – acute generalized exanthematous pustulosis  
AMX – amoxicillin 
APC – antigen presenting cell 
BCR – B cell receptor  
BSA – body surface area 
CBZ – carbamazepine 
CCR – chemokine receptor 
CD – cluster of differentiation 
CLA – cutenaous leukocyte antigen 
Cpm – counts per minute 
CTL – cytotoxic T cell 
DAMP – danger-associated molecular patterns 
DC – dendritic cell  
DHR – drug hypersensitivity reaction 
DIHS – drug-induced hypersensitivity syndrome 
DNA – deoxyribonucleic acid 
DRESS – drug rash with eosinophilia and systemic symptoms 
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DRESS – drug reaction with eosinophilia and systemic symptoms 
EM – erythema multiforme 
FACS – fluorescence-activated cell sorter 
FasL – Fas ligand 
GP – general practitioner 
GVHD – Graft vs Host Disease 
GWAS – genome wide association study 
HLA – human leukocyte antigen 
IFN-y – interferon-gamma 
Ig – immunoglobulin 
IL – interleukin 
ILC – innate lymphoid cell  
LTA – lymphocyte toxicity assay 
LTE – lymphocyte transformation test 
MHC – major histocompatibility complex 
MPE – maculopapular exanthemas 
MRSA – methicillin resistant staphyllocaucus aureus  
NK – natural killer 
NKT – natural killer T cells 
NSAID – non-steroidal anti-inflammatory drugs 
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p-i – direct pharmacological interaction of drugs with immune receptors 
PAMP – pathogen-associated molecular patterns 
PBMC – peripheral blood mononuclear cell  
PBS – phosphate buffered saline, pH = 7.2 
PE – phycoerythrin 
PE-Cy7 – phycoerythrin cyanine-7 
Pen – penicillin  
PMA – phorbol myristate acetate 
R – receptor (ie. IL-4R) 
rANOVA – repeated measures analysis of variance 
RBC – red blood cell  
RNA – ribonucleic acid 
RPMI – Roswell Park Memorial Institute (media)  
RTI – respiratory tract infection 
SI – stimulation index 
SJS – Stevens-Johnson Syndrome 
SJS – Stevens-Johnson Syndrome 
SLE – systemic lupus erythematosus 
SMX – sulfamethoxazole 
SMX-HA – sulfamethoxazole hydroxylamine  
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SMX-NO – nitrososulfonamide 
Strep – streptomycin 
Tc – cytotoxic T cell (also see CTL) 
TCR – T cell receptor 
TEN – Toxic Epidermal Necrolysis 
TGF-b – tumour growth factor 
TH – helper T cell 
TMP – trimethoprim 
TNF – tumor necrosis factor 
TNF-b – tumour necrosis factor 
Treg – regulatory T cells  
UTI – urinary tract infection 
ViD – viability dye 
WHO – World Health Organization 
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Letter of Information 
Letter	of	Information	
	
This	Letter	of	Information	and	the	Informed	Consent	form	are	directed	to	the	participants	in	this	
study.	The	pronouns	‘you’	and	‘your’	should	be	read	as	referring	to	the	participant.		
	
Principle	Investigator:			 Michael	J.	Rieder	MD,	PhD,	FRCPC,	FAAP,	FRCP	(Glasgow)		
Professor,	Departments	of	Paediatrics,	Physiology	&	Pharmacology	
and	Medicine,	Schulich	School	of	Medicine	and	Dentistry,	Western	
University				
	 	 Department	of	Paediatrics		
	 	 London	Health	Sciences	Centre					
	 	 		
	 	
	 	 		
	 	
	
Study	Coordinator:																Abdelbaset	Elzagallaai,	BSc	Pharm,	MSc,	PhD	
Research	Associate	and	Laboratory	Manager,	Department	of	
Pediatrics,	Schulich	School	of	Medicine	and	Dentistry,	Western	
University	
	 Robarts	Research	Institute 	
	 	
	
	 	
	
	 	
	
Graduate	Student:	 	 Christine	Caron,	BSc	Biology,	MSc	candidate	
Graduate	Student,	Department	of	Pathology	and	Laboratory	Medicine,	
Western	University	
Robarts	Research	Institute 	
	
	
		
	
Sponsor:		Canadian	Institutes	for	Health	Research	(CIHR)	
	 	
	
Place	of	Research:			Robarts	Research	Institute,	Western	University		
	
Title	of	Study:	Characterizing	T-cell	phenotype	in	patients	with	hypersensitivity	reactions	to	
sulfonamides	and	beta-lactam	antibiotics		
	
	
Background	
Adverse	drug	reactions	are	a	serious	problem	and	are	among	the	top	five	causes	of	all	deaths	in	
Canada	and	the	United	States.	We	know	that	some	people	who	take	a	drug	suffer	an	adverse	
reaction	while	others	can	take	the	same	drug	without	any	adverse	effects.	Some	of	these	adverse	
reactions	are	mediated	by	cells	in	the	immune	system	that	circulate	through	the	blood.	We	would	
like	to	learn	more	about	how	these	cells	differ	between	patients	with	a	history	of	drug	reaction	
and	those	without.		
	
	
Purpose	of	Study	
The	purpose	of	our	research	is	to	prevent	adverse	drug	reactions	and	the	subsequent	skin	rashes	
through	improved	understanding	of	the	physical	features	of	involved	immune	cells	and	their	
secretions.	These	studies	will	help	to	find	out	what	role	different	cell	types	and	their	respective	
secretions	have	in	predicting	who	will	have	adverse	drug	reactions	and	what	type	of	adverse	skin	
reaction	will	result.		
	
Since	not	all	of	the	immune	cells	and	cell	secretions	involved	in	different	responses	to	drugs	have	
been	discovered	yet,	we	would	like	to	bank	your	biological	sample	to	study	in	the	future.	This	way,	
we	can	go	back	and	test	different	types	of	cells	present	in	your	sample,	or	look	at	different	
secretions	that	those	cells	produce	when	stimulated	with	the	drug.			
	
The	exact	plan	for	these	future	studies	is	not	known	at	this	time	since	it	will	depend	on	other	
discoveries	being	made	in	the	area	of	pharmacological	and	immunological	research.	
		
	
Invitation		
You	are	being	invited	to	participate	in	a	study	looking	at	immune	cells	in	your	peripheral	blood	
(specifically,	blood	from	a	vein	in	your	arm),	and	then	have	the	unused	sample	of	your	cells	
isolated	from	blood	stored	for	future	use	in	research	studies.	This	process	is	referred	to	as	
biobanking.		
	
	
Participation		
Before	you	decide	to	consent,	it	is	important	for	you	know	why	we	wish	to	collect	and	bank	your	
peripheral	immune	cells	and	what	will	be	done	with	them.	This	consent	form	will	tell	you	what	
will	be	collected	and	stored,	where	it	will	be	stored,	who	will	have	access	to	it,	how	it	may	be	used	
in	the	future,	and	the	possible	benefits,	risks,	and	discomforts	associated	with	providing	a	sample.	
	
If	you	wish	to	participate	in	this	study,	you	are	invited	to	sign	this	form.	Participation	in	this	study	
is	voluntary,	therefore	you	have	the	right	to	refuse	to	allow	us	to	obtain	a	blood	sample	and/or	
have	your	isolated	immune	cells	banked.	Refusing	to	participate	or	have	your	cells	banked	will	not	
affect	your	participation	in	this	study	nor	will	refusing	to	participate	in	the	study	as	a	whole	affect	
your	present	or	future	medical	care.	
	
Please	take	time	to	read	the	following	information	carefully	and	to	discuss	it	with	your	family,	
friends,	and	doctor	before	you	decide.			
	
Procedures	
As	part	of	this	study,	a	small	amount	of	your	blood	(approximately	15-20	millilitres,	or	3-4	
teaspoons)	will	be	drawn	using	a	needle	from	a	vein	in	your	arm.	
	
Once	the	blood	is	collected,	the	peripheral	blood	mononuclear	cells	(PBMCs;	immune	cells	that	are	
in	circulation	through	arteries	and	veins)	will	be	isolated.	The	cells	will	be	examined	for	how	they	
respond	to	stimulation	with	the	drug	that	caused	the	adverse	reaction.	Then,	we	would	like	to	take	
a	portion	of	the	isolated	PBMCs	and	freeze	them	for	future	analysis.	Upon	consent,	your	samples	
will	be	labelled	with	a	unique	numeric	code	so	that	your	name	will	not	be	attached	to	the	sample.	
Only	the	study’s	Principal	Investigator	and	his	designates	will	hold	the	key	containing	your	unique	
numeric	code	with	your	identifying	information.	This	sample	will	be	held	frozen	at	Robarts	
Research	Institute,	Western	University.		
	
We	are	also	asking	your	permission	to	keep	some	information	obtained	from	your	medical	
records.	This	information	is	only	pertinent	to	the	adverse	drug	reaction	you	experienced	to	
sulfamethoxazole	or	beta-lactam	antibiotics.	Only	the	relevant	information	obtained	from	these	
records	will	be	stored	in	our	secure	study	databases	located	at	Robarts	Research	Institute.	This	
information	will	be	identified	using	the	same	study	identity	number	as	the	biological	sample.	No	
information	that	could	identify	you	personally	will	be	included.		Only	the	study	investigators	will	
have	access	to	the	database.		
	
Every	measure	will	be	taken	to	ensure	your	privacy.	The	cells	you	provide	will	only	be	used	for	
research	described	in	this	consent	form.	You	will	not	receive	the	results	of	this	or	any	future	tests.	
Your	participation	in	this	study	will	not	become	part	of	your	medical	record.	The	analyses	
conducted	by	our	investigators	are	focused	on	the	response	of	cells	upon	stimulation	by	the	
specific	drug	you	have	an	adverse	reaction	to	and	a	control	stimulant.	Therefore	it	is	extremely	
unlikely	that	we	will	uncover	any	new	information	relevant	to	your	health	or	overall	
wellbeing.	However,	in	the	rare	event	that	this	occurs,	the	biobank	will	be	requested	to	re-identify	
you	so	that	we	can	notify	your	physician	of	our	findings.	
	
	
Responsibilities	
After	your	blood	sample	has	been	taken	you	do	not	need	to	do	anything	else	to	participate	in	this	
study.	
	
	
Risks	and	Discomforts	
Blood	withdrawing	is	identical	to	any	blood	sample	taking	for	routine	blood	tests	at	a	hospital	or	a	
medical	lab.	The	possible	harms	and	discomforts	of	the	study	mostly	involve	the	collection	of	the	
blood	sample.	There	may	be	some	slight	pain	and	discomfort	when	the	needle	is	inserted	into	the	
vein	for	blood	collection,	and	some	minor	bleeding,	bruising,	swelling,	or	feeling	faint	or	dizzy	
after	it	is	removed.	
	
	
	
Benefits	
The	research	that	may	be	done	with	your	biological	sample	is	not	expected	to	benefit	you	or	your	
family	members	directly.	However,	we	hope	that	the	information	gained	from	these	studies	can	be	
used	in	the	future	to	improve	the	safety	and	efficacy	of	beta-lactam	antibiotics	and	
sulfamethoxazole.	
	
	
Withdrawal	
It	is	possible	to	withdraw	from	the	study	at	any	stage	upon	your	request.	All	your	samples	will	be	
properly	destroyed	and	data	will	be	deleted.	
	
	
Confidentiality		
Protecting	your	privacy	is	our	number	one	priority.	Your	rights	to	privacy	are	legally	protected	by	
federal	and	provincial	laws	that	require	safeguards	to	ensure	that	your	privacy	and	personal	data	
are	respected.	These	laws	also	give	you	the	right	of	access	to	the	information	that	has	been	
provided	and,	if	need	be,	an	opportunity	to	correct	any	errors	in	this	information.	In	most	cases,	
your	personal	information	or	information	that	could	identify	you	will	not	be	revealed	to	any	third	
party,	including	your	family	members	and	your	physician,	without	your	expressed	consent.		
	
You	will	be	assigned	a	unique	study	code	number	as	a	participant	in	this	study.	This	number	will	
not	include	any	personal	information	that	could	identify	you	(for	example	it	will	not	include	your	
Ontario	Health	Insurance	Card	number,	or	Social	Insurance	Number,	your	initials,	etc.).	Only	this	
number	will	be	used	on	any	research-related	information	collected	about	you	during	the	course	of	
this	study,	so	that	your	identity	will	be	kept	confidential.	Only	the	Principal	Investigator,	the	study	
coordinator,	and	the	person	collecting	your	blood	sample	will	have	access	to	the	names	of	
participants	in	this	study.	Lists	of	participants	will	be	kept	locked	in	the	office	of	the	study	
coordinators.	All	computer	files	will	be	kept	encrypted	and	locked	with	restricted	access	
passwords	known	only	to	the	investigators.	Information	about	the	drugs	you	take	and	your	blood	
sample	will	be	sent	to	our	analysis	center,	at	the	Robarts	Research	Institute,	for	analysis.	
	
No	information	or	records	that	disclose	your	identity	will	be	published,	nor	will	any	information	
or	records	that	disclose	your	identity	be	removed	or	released	without	your	consent	unless	
required	by	law.		
	
Name,	address,	and	phone	number	are	collected	in	the	rare	instance	that	we	need	to	contact	you	
regarding	any	unclear	information.	This	extra	contact	will	be	minimal,	and	we	do	not	expect	to	
contact	every	patient	enrolled.		
	
Since	your	sample	and	information	will	be	kept	for	many	years	or	until	it	is	used	entirely	or	
withdrawn,	we	will	update	our	security	measures	for	protecting	your	data	and	for	preserving	your	
sample	as	they	become	available.		
	
	
	
	
Contact	Person(s)	for	Participants	
If	you	have	any	questions	about	the	study	and/or	treatment	and	care,	you	may	contact	Dr.	
Abdelbaset	(Baset)	Elzagallaai,	the	study	coordinator 	
	or	Christine	Caron 		
	
	
No	Waiver	of	Rights	
You	do	not	waive	any	legal	rights	by	signing	this	consent	form.	
	
Consent	Form	–	Research	Copy	
	
Title	 of	 Study:	 Characterizing	 T-cell	 phenotype	 in	 patients	 with	 hypersensitivity	 reactions	 to	
sulfonamides	and	beta-lactam	antibiotics	
	
I	have	read	the	accompanying	letter	of	information	and	have	had	the	nature	of	the	study	explained	
to	me	and	I	agree	to	participate	in	the	study.	All	questions	have	been	answered	to	my	satisfaction.			
	
	
Participant’s	Date	of	Birth	 	
	
	
		 																																																																				 	
Participant’s	Name	(please	print)	 Name	of	Person	Obtaining	Informed	Consent	(please	print)	
	
	
		 																																																																				 	
Participant’s	(or	Guardian’s)	Signature		 Signature	of	Person	Obtaining	Informed	Consent		
	
	
Date	 	 										Date	 	
	
	
	 	
Consent	Form	–	Participant	Copy	
	
Title	 of	 Study:	 Characterizing	 T-cell	 phenotype	 in	 patients	 with	 hypersensitivity	 reactions	 to	
sulfonamides	and	beta-lactam	antibiotics	
	
I	have	read	the	accompanying	letter	of	information	and	have	had	the	nature	of	the	study	explained	
to	me	and	I	agree	to	participate	in	the	study.	All	questions	have	been	answered	to	my	satisfaction.			
	
	
Participant’s	Date	of	Birth	 	
	
	
		 																																																																				 	
Participant’s	Name	(please	print)	 Name	of	Person	Obtaining	Informed	Consent	(please	print)	
	
	
		 																																																																				 	
Participant’s	(or	Guardian’s)	Signature		 Signature	of	Person	Obtaining	Informed	Consent		
	
	
Date	 	 										Date	 	
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Curriculum Vitae 
Academic	Background	
September	2017	–		
August	2020	
Western	University	
Master	of	Science	in	Pathology	and	Laboratory	Medicine	
student	under	the	supervision	of	Dr.	Michael	Rieder	
January	2014	–		
April	2017		
Algoma	University	
Undergraduate	student	in	Honours	Bachelor	of	Science	in	
Biology,	minor	in	Psychology	
	
Awards	and	Scholarships	Received	
2018	 Dr.	Frederick	Winnett	Luney	Graduate	Research	Award	
2017	 NSERC-USRA	Scholarship	
Algoma	University	Dean’s	Honour	List	
2016	 Algoma	University	Academic	Achievement	Scholarship	
NSERC-USRA	Scholarship	
Algoma	University	Dean’s	Honour	List	
2015	 Algoma	University	Academic	Achievement	Scholarship	
NSERC-USRA	Scholarship	
Algoma	University	Dean’s	Honour	List	
2014	 Lake	Superior	State	University	Dean’s	List	
2013	 Lake	Superior	State	University	Canadian	Student	Entrance	
Scholarship	
Sault	Ste.	Marie	Zonta	Scholarship	
Kewadin	Club	Scholarship	
	
Work	Experience	
	
September	2018	–	
present		
Graduate	Teaching	Assistant	(full	time,	140	hours	per	semester)	
–	Western	University,	Department	of	Biology:	Introductory	
Biology	(BIOL1001/1201A,	BIOL1002/1202A)	skills	sessions	B	
teaching	assistant,	involves	co-leading	approximately	40	
students	through	a	wet	lab	environment,	grading	assignments,	
proctoring	midterms	and	final	exams,	entering	grades	
	
May	2017	–		
August	2017;	
May	2016	–		
August	2016;	
May	2015	–			
August	2015,		
	
NSERC	Undergraduate	Student	Research	Assistant	–	Algoma	
University:	Received	NSERC-USRA	grant	to	work	in	Algoma	
University’s	plant	biochemistry	lab	under	the	supervision	of	Dr.	
Isabel	Molina	on	projects	involving	the	study	of	suberin	
deposition	in	poplar	trees	
September	2015	–	
April	2016	
Research	Assistant	–	Algoma	University,	Department	of	Biology:	
Worked	in	plant	biochemistry	lab	at	Algoma	University	under	
the	supervision	of	Dr.	Isabel	Molina,	studying	suberin	deposition	
in	poplar	tree	studies		
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January	2015	–	
December	2015	
Teaching	Assistant	–	Algoma	University,	Department	of	Biology:	
Introductory	Chemistry	(CHMI1006)	course	teaching	assistant;	
duties	involved	helping	students,	grading	tests,	quizzes,	
assignments,	and	holding	tutorial	sessions	for	the	classes	
	
September	2014	–	
December	2014	
Teaching	Assistant	–	Algoma	University,	Department	of	Biology:	
Introductory	chemistry	(CHMI1006)	lab	teaching	assistant;	
duties	included	supervising	the	students	during	lab	experiments,	
answering	questions,	and	helping	the	lab	instructor		
	
September	2014	–		
April	2016	
Tutor	–	Algoma	University:	Tutor	for	a	variety	of	subjects,	
including	general	chemistry	and	organic	chemistry	
	
Research	Experience	
	
September	2017	–	
present		
Western	University	–	London,	Ontario:	MSc	student	
• Supervisor	Dr.	Michael	Rieder	
• Project	involves	studying	pathophysiology	of	drug	
hypersensitivity	reactions,	specifically	culturing,	
stimulating,	and	staining	immune	cells,	and	assessing	
phenotype	and	cytokines		
2015	–	2017	 Algoma	University	–	Sault	Ste.	Marie,	Ontario:	NSERC-USRA	
Scholarship	
• Supervisor	Dr.	Isabel	Molina	
• Involved	in	continual	research	experiments	surrounding	
Populus	sp.	wounding	experiments	and	mutant	analysis	
August	2016,		
August	2017	
University	of	California	San	Diego	–	San	Diego,	California	
• Part	of	NSERC-USRA	scholarship	
• Supervisor	Dr.	Laurie	Smith,	collaboration	with	Dr.	Isabel	
Molina	
• Collecting	and	phenotyping	corn	leaves	as	part	of	
National	Science	Foundation	project	on	drought-resistant	
maize	
2016	–	2017	 Algoma	University	–	Sault	Ste.	Marie,	Ontario:	Thesis	student	
• Supervisor	Dr.	Isabel	Molina		
• Involved	in	determining	gene	responsible	for	unique	bark	
phenotype	in	Populus	717	mutant	using	forward	genetics	
and	to	determine	whether	mutation	is	related	to	suberin	
deposition	
2015	–	2016	 Algoma	University	–	Sault	Ste.	Marie,	Ontario	
• Supervisor	Dr.	Isabel	Molina	
• Plant	Biochemistry	
• Hired	part-time	to	begin	growing	cuttings	of	mutant	
Populus	ssp.	717	mutant	and	performing	lipid	analyses	on	
suberin	and	associated	waxes,	while	also	performing	
general	lab	duties	such	as	TLC	on	other	lab	projects	
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Conference	Experience	
	
June	2019	 Canadian	Society	of	Pharmacology	and	Therapeutics	Joint	Annual	
Conference,	“From	Base	to	Summit:	Pharmacology	at	its	Peak”,	
Calgary,	Alberta	
Presented	poster	Investigating	the	Pathophysiology	of	T-Cell	
Mediated	Drug	Hypersensitivity	Reactions	
April	2019	 London	Health	Research	Day,	London,	Ontario	
• Presented	poster	Investigating	the	Pathophysiology	of	T-Cell	
Mediated	Drug	Hypersensitivity	Reactions	
March	2019	 Western	University	Department	of	Pathology	Research	Day,	
London,	Ontario	
• Presented	poster	Investigating	the	Pathophysiology	of	T-Cell	
Mediated	Drug	Hypersensitivity	Reactions	
June	2018	 Robart’s	5th	Annual	Research	Retreat,	London,	Ontario	
• Presented	poster	Investigating	the	Pathophysiology	of	T-Cell	
Mediated	Drug	Hypersensitivity	Reactions	
May	2018	 Canadian	Society	of	Pharmacology	and	Therapeutics	Joint	Annual	
Conference,	“Translating	Innovative	Technology	to	Patient	Care”,	
Toronto,	Ontario	
• Presented	poster	Investigating	the	Pathophysiology	of	T-Cell	
Mediated	Drug	Hypersensitivity	Reactions	
London	Health	Research	Day,	London,	Ontario	
• Presented	poster	Investigating	the	Pathophysiology	of	T-Cell	
Mediated	Drug	Hypersensitivity	Reactions	
April	2018	 Western	University	Department	of	Pathology	Research	Day,	
London,	Ontario		
• Presented	poster	Investigating	the	Pathophysiology	of	T-Cell	
Mediated	Drug	Hypersensitivity	Reactions	
March	2017	
	
Ontario	Biology	Day	2017	Undergraduate	Conference	at	
Laurentian	University,	Sudbury,	Ontario	
• Presented	undergraduate	thesis	poster	Characterization	of	
a	Mutant	Poplar	Hybrid	(Populus	sp.)	with	an	Abnormal	Bark	
Phenotype	
	 • 	
	
Leadership,	Outreach,	and	Volunteer	Experiences	
	
October	2018—
present		
Vice	President	of	Social	Events	with	Western	Pathology	
Association	
• Planning	social	events	for	undergraduate	and	graduate	
students	as	well	as	staff	and	faculty	in	the	Pathology	
department	to	help	with	teambuilding	and	morale	
May	2018	 Volunteer	at	Science	Rendezvous	event	with	the	Western	
Pathology	Association’s	“Crime	Scene	Investigation”	booth	at	
Western	University,	London,	Ontario	
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April	2017	 Volunteer	at	Sault	Ste.	Marie’s	Science	Festival	“Hangar	After	
Dark”	event	at	the	Canadian	Bushplane	Heritage	Centre,	Sault	
Ste,	Marie,	Ontario		
2015—2016	 President	of	the	Algoma	University	Biology	Club	
April	2016	 Science	Fair	at	Algoma	University	
• Presented	overview	of	ongoing	research	conducted	in	Dr.	
Isabel	Molina’s	laboratory	
January	2015—	
April	2016	
General	Chemistry	Teaching	Assistant	
• Created	and	conducted	tutorial	sessions	for	first	year	
students		
September	
2014—	
April	2015	
Community	Ecology	Lab	Volunteer	
• Duties	included	sorting	and	counting	seeds	of	various	
species	after	collection	from	field	for	future	analysis	and	
experimentation		
September	
2014—December	
2014	
General	Chemistry	Lab	Teaching	Assistant	
• Aided	students	in	performing	lab	experiments	for	first	
year	general	chemistry	
 
